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Isoniazid (INH) serves as the backbone of combined anti-tuberculosis therapy. However, the 
effectivity of this drug has been compromised due to increasing resistance to it in 
Mycobacterium tuberculosis (M. tuberculosis). This resistance arises through spontaneous 
mutations in certain genes/genomic regions of M. tuberculosis. The current drug resistance 
testing algorithm for INH consists of a genotypic MTBDRplus line-probe assay (LPA), which 
reports resistance to INH based on mutations in katG gene and inhA promoter, and a 
phenotypic drug susceptibility test (DST), used to confirm INH susceptibility in rifampicin 
resistant cases on LPA. However, the algorithm is problematic as there are discrepancies 
between mutations causing INH resistance detected on LPA and phenotypic DST. This may 
result in incorrect diagnoses and the prescription of incorrect drug treatment regimens. The 
current study investigates 398 clinical isolates obtained from NHLS Port Elizabeth with 
discrepant status between the LPA and the phenotypic DST. The isolates were investigated by 
means of a series of standardized methods such as Sanger sequencing, Whole Genome 
Sequencing and spoligotyping. This was done to determine if the reasons for the discrepancies 
between the LPA and phenotypic DST were due to novel mechanisms of resistance to INH. 
Genotyping via spoligotyping indicated a prevalence of the Beijing genotype in this cohort, as 
well as mixed infections and novel spoligotype patterns that don’t resemble any known 
lineage or family markers. Sanger sequencing revealed canonical mutations that were missed 
by the LPA as well as mutations occurring elsewhere in the katG gene, indicating there are 
blind spots in the LPA that may have detrimental effects on patient response to treatment. Per 
the whole genome sequencing results, novel mechanisms were associated with spontaneous 
non-canonical single nucleotide polymorphisms in M. tuberculosis. These polymorphisms 
occurred in genetic regions outside the LPA region of hybridisation and conferred varying 
levels of resistance to INH.   The clinical isolates in this dataset consisted of 29.2% low-level 
resisistant (minimum inhibitory concentration between 0.1-1.0 µg/L to INH) and 61%  high-
level resistant (minimum inhibitory concentration of > 1µg/ml to INH) isolates.The degree of 
resistance to INH is relevant, as it informs prescription of treatment regimens. It is 
recommended that cases of low-level resistance to INH be treated with the short course 
Bangladesh regimen consisting of high dose INH, whereas high-level resistance to INH 
requires the removal of this antibiotic from the regimen.Homologous recombineering was 
also done to functionally confirm the role these novel mechanisms have on INH resistance, 
and the subsequent level of resistance caused. The results obtained in this study will 
ultimately be used to improve current diagnostic methods for detection of INH resistance. 





Isoniazid (INH) dien as die ruggraat van gekombineerde anti-tuberkulose terapie. Tans is die 
effektiewiteit van hierdie antibioika in gedrang as gevolg van toenemende weerstand daarteen 
in Mycobacterium tuberculosis (M. tuberculosis). Hierdie weerstand ontstaan deur spontane 
mutasies in sekere gene/genotipiese streke van M. tuberculosis. Die huidige middel weerstand 
toets algoritme vir INH bestaan uit 'n genotipiese MTBDRplus (LPA) toets, wat INH 
weerstandigheid rapporteer gebaseer op mutasies in katG gene en inhA promotor, en 'n 
fenotipiese middel vatbaarheid toets (DST), gebruik om INH vatbaarheid te bevestig in 
rifampisien weerstandige gevalle op LPA. Die algoritme is egter problematies omdat daar 
teenstrydighede is tussen mutasies wat INH weerstand veroorsaak op LPA en fenotipiese 
DST. Dit kan lei tot verkeerde diagnoses en die voorskrif van verkeerde behandeling vir 
tuberkulose. Die huidige studie ondersoek 398 kliniese isolate van NHLS Port Elizabeth met 
teenstrydige weerstandigheids status tussen die LPA en die fenotipiese DST. Die isolate is 
ondersoek deur middel van gestandardiseerde metodes soos Sanger volgordebepaling, hele 
genoom volgordebepaling (WGS) en spoligotipering. Dit was gedoen om die redes vir die 
teenstrydighede tussen die LPA en fenotipiese DST te bepaal. Spoligotipering het aangedui 
dat die meeste isolate in die studie aan die Beijing genotipe behoort, sowel as gevalle van 
gemengde infeksies en onbekende patrone. Sanger volgordebepaling het klassieke mutasies 
wat deur die LPA gemis was asook mutasies wat elders in die katG geen,voorkom-
gediagnoseer, wat aandui dat daar blinde kolle is in die LPA. Die blinde kolle mag ‘n nadelige 
effek hê op die behandeling van die pasient. Volgens die hele genoom volgordebepaling 
resultate, het die unieke meganismes van weerstand gepaardgegaan met punt mutasies in M. 
tuberculosis. Hierdie mutasies het voorgekom in genetiese streke buite die wat ondersoek 
word deur die LPA en verleen wisselende vlakke van weerstand teen INH. Die kliniese isolate 
in hierdie studie bestaan uit 29.2% lae-vlak weerstandige (minimum inhiberende konsentrasie 
tussen 0.1-1.0 μg/L tot INH) en 61% hoëvlak weerstandige (minimum inhiberende 
konsentrasie van > 1µg/ml tot INH) isolate. Die vlak van weerstand teen INH is belangrik, 
aangesien dit die voorskrif van antibiotika vir behandeling beinvloed. Ons beveel aan dat 
gevalle van lae-vlak weerstand tot INH behandel word met die kort kursus Bangladesh 
antibiotika kursus wat bestaan uit hoë dosis INH, terwyl hoëvlak weerstand teen INH vereis 
dat INH uitgesluit word vir behandeling. Homologosiese rekombinasie is gedoen om 
funksioneel te bevestig dat die rare mutasies ‘n rol het in INH weerstand. Die resultate verkry 
in hierdie studie sal uiteindelik gebruik word om huidige diagnostiese metodes vir die 
opsporing van INH weerstand te verbeter. 
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Chapter 1 - General Introduction




Aerosolised Mycobacterium tuberculosis (M. tuberculosis) bacilli are causative of the 
infectious disease tuberculosis. Its infectious nature has ensured that the TB epidemic is a 
health concern worldwide. Per statistics supplied by the World Health Organization 
(WHO), tuberculosis is the third leading cause of mortality due to infectious disease[1]. 
This disease is particularly dangerous when it presents in persons that are immuno-
compromised. 
To combat TB, a strict regimen of combined drug therapy is prescribed. This involves 
taking multiple antibiotics simultaneously to maximize their effects and protect the various 
drugs. The first-line drugs that are generally prescribed according to the standard regimen 
recommended by WHO consist of rifampicin, isoniazid, ethambutol and pyrazinamide[2]. 
The first line drug isoniazid (INH) serves as a central component of combined anti-
tuberculosis drug therapy. This drug is bactericidal against actively replicating bacilli and 
bacteriostatic against latent infections[3]. The mechanism of action of activated INH is to 
target the type 2 fatty acid synthase (FAS II) system responsible for mycolic acid synthesis 
within M. tuberculosis[4]. 
Prior to its entry into M. tuberculosis cells, INH remains inactive and is not harmful to M. 
tuberculosis. However, upon diffusion into the mycobacterial cells it becomes activated via 
peroxidation by the KatG catalase peroxidase enzyme (produced by the mycobacterial 
katG gene)[5]. 
Under ideal conditions M. tuberculosis is extremely vulnerable to INH. However, this 
bacterium is notoriously tenacious and cases of resistance to INH emerged soon after its 
implementation as an anti-tuberculosis drug in 1952[6]. This resistance to INH arises 
through spontaneous mutations in the genetic make-up of M. tuberculosis, changing its 
genome and interfering with the mechanism of the anti-tuberculosis drugs. Of these 
mutations that confer INH resistance, the most well-known are mutations in katG and the 
inhA promoter. However, many examples of M. tuberculosis strains that display resistance 
despite lacking mutations in katG and the inhA promoter are described in the literature[7]–
[10]. Some other genes that have been implicated in INH resistance include mutations in 
ahpC-oxyR intergenic region[11], kasA gene[12], inhA gene[12] and fabG-inhA regulatory 




region[13] to name but a few. Knowledge of how these mutations contribute to resistance 
may be used in future to combat the increase in isoniazid mono-resistant and multi-drug 
resistant (MDR) tuberculosis, and to improve current diagnostic methods.  
Traditionally, phenotypic tests have been employed in the South African drug resistance 
testing algorithm for isoniazid. However, while phenotypic methods such as MIC testing 
are popular in resource poor settings due to their low cost, they are time consuming 
because of the slow growth rate of M. tuberculosis. Thus, the implementation of molecular 
methods has become necessary to diagnose drug resistance in M. tuberculosis and speed up 
diagnosis, as well as to ensure a patient is on the correct treatment regimen. These methods 
function on a genotypic level to detect mutations of the M. tuberculosis genome that are 
associated with drug resistance[14]. 
As mutations in katG, inhA promoter, kasA[12]and the oxyR-ahpC intergenic region[11] are 
associated with INH resistance, these must be screened for first to obtain a faster diagnosis 
of INH resistance. The Line Probe Assay (LPA) MTBDRplus is a molecular method that 
can partially achieve this, as it screens for mutations in regions of katG and inhA promoter 
which are known to be associated with INH resistance[14]. The LPA tests specifically for 
mutations in katG 315 (S315T1 and S315T2) as these mutations are most commonly 
associated with resistance to INH (Zhang and Yew, 2009), as well as -15 (C15T), -16 
(A16G) and -8 (T8C/ T8A) mutations in the inhA promoter[15]. Thus, any mutations that 
cause INH resistance, but occur outside of these specific regions will be missed by the 
LPA, thereby misdiagnosing the patient as INH susceptible. 
The LPA method involves isolating bacterial deoxyribonucleic acid (DNA) from the M. 
tuberculosis isolate, amplifying the DNA via polymerase chain reaction (PCR) and then 
observing the hybridization to a probe with a biotin tag. If the probe is bound, a band will 
be visible. Probes on the GenoType MTBDRplus[16] are designed to indicate the presence 
or absence of M. tuberculosis, INH resistance by the markers described above, and 
rifampicin resistance[15],[17]. 
As this test has a better positive predictive value for rifampicin (RIF) resistance compared 
to INH resistance, a secondary phenotypic drug susceptibility test (DST) must be done to 
confirm INH susceptibility in cases reported as RIF mono-resistant on the LPA. However, 




there may be discrepancies between mutations causing INH resistance detected on 
molecular testing and phenotypic DST[14]. 
The discrepancies between the two tests for INH resistance may result in incorrect 
diagnoses and thus the prescription of incorrect drug treatment regimens to patients. This 
project is based on the hypothesis that the discrepancies between LPA and DST are due to 
unknown mechanisms of resistance. Thus, we endeavor to verify the accuracy of routine 
DST (LPA and phenotypic) through Sanger sequencing and diagnose mixed infections or 
heteroresistance via spoligotyping. Additionally, we identify novel mechanisms of 
resistance to the first line anti-tuberculosis drug isoniazid through Whole Genome 
Sequencing (WGS) analysis, followed by validation of selected candidates through 
recombineering and minimum inhibitory concentration determination. Ultimately, these 
findings will aid to improve current diagnostic methods. 
1.2 Problem Statement 
There are discrepancies between the genotypic and phenotypic tests for INH resistance, 
which may result in incorrect diagnoses and the subsequent prescription of an incorrect 
drug treatment regimen to patients. 
1.3 Hypothesis 
The discrepancies between LPA and DST are due to unknown mechanisms of resistance, 
outside the region of hybridization of the LPA. 
1.4 Aims 
We aim to identify the reason for discrepancies between the LPA and DST and if no 
conventional reason can be elucidated, to investigate novel mechanisms of resistance. 
 
 





1. To identify the reason for discrepancies between genotypic and phenotypic INH 
resistance testing via MIC, Spoligotyping and Sanger sequencing. 
2. To identify unknown mechanisms of resistance to INH via whole genome 
sequencing. 
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Abstract: Background: The first-line TB antibiotic isoniazid (INH) serves as a central 
component of combined first-line anti-tuberculosis drug therapy. However, resistance to 
INH has hindered the functioning of this drug. Resistance is caused by several known and 
unknown mutations in genes/regions in Mycobacterium tuberculosis (M. tuberculosis), 
followed by selection of these mutants in the presence of the drug. INH resistance can be 
categorised as either “high-level” (minimum inhibitory concentration (MIC) of > 1µg/ml to 
INH) or “low-level” (MIC between 0.1-1.0 µg/L) resistance and is dependent on the 
specific mutation acquired. The level of resistance is relevant, as INH resistance is often 
considered to be the first step in development of multi-drug resistant (MDR) and extremely 
Resistant (XDR) TB. Isoniazid is a pro-drug in which first pass metabolism happens via N-
acetyltransferase and is fast, intermediate or slow, depending on the genetics of the host. 
Thus, low-level INH resistance, particularly in the presence of fast metabolism, could 
allow additional mutations, development of high-level resistance and progression to multi-
drug resistance. 
 
Methods: A structured search of bibliographic databases for peer-reviewed research 
literature was performed. Set parameters and specific inclusion criteria where used to filter 
the literature, based on our specified review questions. The quality and relevance of 
included papers was deduced using standard tools. The relevant content of cited papers was 
described, and an inferential qualitative content analysis methodology was utilised to 
analyse the inferences and findings of included studies using a conceptual framework. 
 
Results: Seventy-eight papers were included in the review, of which a sub-set (36) of the 
papers describe how different genetic mutations result in low or high-level resistance to 
INH. These papers were also used to set up a diagram detailing how each mutation affects 




INH functionality in order to visualise the interactome of INH and M.tuberculosis A 
further twenty-eight out of the seventy-eight papers detail the methods for testing for INH 
resistance, current treatment regimens and factors that influence treatment outcome in 
order to better understand the role of INH within the current anti-tuberculosis treatment 
therapy and how its use can be optimised. 
 
Conclusion: The findings of this review suggest that low-level INH resistance, in the 
presence of fast-acetylation, is an underrated component of the global TB epidemic 
worldwide, and may be a significant problem in terms of treatment outcome and 
progression to antibiotic resistance. Thus, more research must be done to test whether 
personalised diagnostics and targeted high dose treatment with INH will reduce the 
incidence of isoniazid mono-resistant and multi-drug resistant (MDR) tuberculosis. 
 
Keywords: Low-level resistance, dosage, tuberculosis, isoniazid, resistance, 
metabolism and acetylation. 
INTRODUCTION 
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(henceforth referred to as M. tuberculosis). Its infectious nature, together with its 
propensity for antibiotic resistance, has ensured that the TB epidemic is a global health 
concern.  
To treat TB, a strict regimen of extended combined drug therapy is prescribed. The first-
line drugs that are recommended consist of rifampicin, isoniazid (INH), ethambutol and 
pyrazinamide[2]. This current drug treatment regimen and dosage was developed after 
extensive trials, and although it is currently considered best practice, it is not perfect[3],[4]. 
For example, this multi-drug regimen for TB treatment can lead to hepatotoxicity in some 
individuals[5]. Anti-TB drug-induced hepatotoxicity ranges from 1% to 36%, and mortality 
within this group is not uncommon[6],[7]. Additionally, treatment failures can also occur 
under certain conditions, however it is important to note that the current drug regimen 
generates successful outcomes for most, provided there is adherence and no antibiotic 




resistance[6]. Out of all the drugs in the regimen, INH has been found to be the greatest 
contributor to drug-induced hepatotoxicity[5],[7], and a better understanding of isoniazid 
metabolism and treatment modification may provide a solution. 
INH specifically, serves as an integral component of combined first-line drug therapy. This 
first-line drug serves as the backbone of treatment for drug sensitive tuberculosis 
infections, as it is bactericidal against actively replicating bacilli[8], and is also responsible 
for much of the early bactericidal activity  of the multi-drug regimen[9]. INH is also 
bacteriostatic against latent infections[8], and is recommended for preventative therapy[10]. 
For overburdened health care systems to function optimally, cost effective standardised 
therapies that serve to manufacture and deliver drugs in the most effective way may be 
desirable. This is especially true for therapies for diseases that have reached epidemic 
status, such as tuberculosis. Thus, it is for TB treatment, where a standardised dose for 
INH is provided. However, despite the advantages of standardised therapy, it may not be 
the most effective treatment in some cases[4]. Therefore, it behoves us to think more 
carefully about INH usage. While dosage per weight is a factor that we can easily control 
for, factors involved in metabolism of isoniazid are more complicated and need careful 
consideration. For example, high concentrations of drug, or certain metabolic products may 
result in adverse effects, limiting dosage. In turn, a limited dosage either administered in 
attempt to avoid adverse events or from rapid degradative metabolism may result in 
relatively low levels of INH, which may predispose the target organism to develop 
antibiotic resistance. In the case of already existing low-level M. tuberculosis isoniazid 
resistance due to genomic mutations, the host is placed at potential risk for the 
development of high-level INH resistance or resistance to additional drugs[11]. 
In the context of the information provided thus far, it is not surprising that INH mono-
resistance develops commonly and is widespread. In fact, 4.9% of tuberculosis cases in 
South Africa were found to be INH mono-resistant per a survey between 2012 and 2014 by 
the National Institute for Communicable Diseases[12]. In agreement with this finding, the 
worldwide prevalence of mono-resistance to INH is between 4–13% for all TB cases with 
a global average of 8.1% for new TB cases[13],[14]. It is also suspected to be the stepping 
stone for development of further resistance[15], progressing to MDR, XDR and what might 
be regarded as totally resistant TB cases.    




Some important considerations regarding the use of isoniazid are (not in priority order); 1) 
absorption, 2) host body mass index (BMI), 3) host tolerance, 4) host metabolism, 5) 
concomitant host health problems, such as HIV infection or diabetes, 6) microbial 
metabolism and 7) microbial resistance. If we understand the factors involved in INH 
metabolism for example (particularly fast metabolism), and low-level resistance in M. 
tuberculosis, we might justify modifying the fixed dose regimen. A higher INH dose may 
pose extra risk for adverse events of course, but the benefit gained may outweigh such risk 
if patients are monitored carefully. This review proposes to justify this hypothesis. 
1. Isoniazid: Mechanism of Action against M. tuberculosis  
 
Isoniazid is a pro-drug that, in its activated form, is effective against actively replicating M. 
tuberculosis. Upon diffusion into the mycobacterial cells, INH becomes activated via 
peroxidation by the KatG catalase peroxidase enzyme (produced by the mycobacterial 
katG gene)[16]. The target of activated INH within the bacillus is the type 2 fatty acid 
synthase (FAS II) system responsible for mycolic acid synthesis in M. tuberculosis[17]. 
Mycolic acids are essential components of the unique mycobacterial cell wall, along with 
peptidoglycan and arabinogalactan[18]. Mycolic acids form part of the waxy layer of 
mycobacteria and also play a role in cording[19]. Importantly, mycolic acids assist in M. 
tuberculosis survival in sub-optimal conditions for extended periods of time[20]. Thus, by 
preventing the synthesis of mycolic acids, INH is directly affecting the ability of M. 
tuberculosis to survive under most conditions within the host and renders it more 
susceptible to killing by other antibiotics. 
The current model for the INH mechanism of action in the M. tuberculosis bacillus 
suggests that the katG-mediated activation of INH results in reactive organic species 
known as isonicotinic-acyl radical or anion, as well as reactive oxygen species such as 
superoxide and electrophilic species[8]. The isonicotinic-acyl radical or anion reacts 
covalently with NAD(H) to form an INH-NAD Adduct. It is suspected that the NAD(H) 
co-factor binding involved in the Adduct may bring about a conformational change that 
renders InhA more accessible to INH[21]. It is the modified INH that targets InhA (enoyl-
acyl carrier protein reductase), which is thought to be the primary target of INH inhibition 
as well as being involved in elongation of fatty acids in mycolic acid synthesis[8],[22]. The 




INH-NAD Adduct binds to InhA, thus blocking its activity[21]. The elongation of C16 and 
C24 fatty acids are prevented within the FAS II (fatty acid elongation system) and thus 
mycolic acid synthesis is blocked, leading to cell death[23],[24]. Thus, the current 
understanding is that activated INH targets the active site of enoyl acyl carrier protein 
(ACP) reductase, named InhA, within the FAS II system[25]. However, an alternative 
metabolic pathway for INH exists in the bacillus. Specifically, the nat gene of M. 
tuberculosis (known as “tbnat”) has also been postulated to play a role in INH 
susceptibility in combination with other factors[26]. This gene encodes a microbial 
arylamine N-acetyltransferase (NAT) enzyme. It was first documented in M. tuberculosis 
in 1999[27], and it has been shown to be expressed only in active M. tuberculosis cells[28]. 
Additionally, tbnat occurs in a gene cluster that is vital for the survival of M. tuberculosis 
in macrophages[28]. The level of expression may vary per polymorphic forms and exposure 
to inducing agents such as INH. Payton et al. showed in 1999 that overexpression of the M. 
tuberculosis nat gene in Mycobacterium smegmatis, resulted in a threefold increase in 
resistance[27]. In addition, they showed that tbnat can N-acetylate INH under in vitro 
conditions[27].The activation of INH in M. tuberculosis via catalase-peroxidase activity 
cannot occur if INH is N-acetylated[26],[29]. There is therefore some evidence to suggest that 
some variants or expression levels of this enzyme, although rare, may contribute to INH 
resistance in conjunction with various other factors[26]. 
 
2a. M. tuberculosis genes associated with isoniazid resistance and the level 
of resistance 
Unfortunately, resistance to INH emerged soon after its introduction as an anti-tuberculosis 
drug[30]. In M. tuberculosis, resistance is not plasmid encoded, but arises through mutations 
in genes/regions in the genome which may alter the processing of antibiotics and lead to 
resistance. Of the mutations that confer INH resistance, the most well-known are in the 
katG gene and the inhA promoter[31],[32]. Some other genes that have been implicated in  
INH resistance include mutations in ahpC-oxyR intergenic region[33], kasA gene[34] and 
inhA gene[34]. However, other genes and gene mutations have been implicated in INH 
resistance or susceptibility but their mechanisms are not yet well understood[32]. Genes 
associated with INH resistance have been summarised in Table 1. 











                                                          
*
1 High-level resistance: MIC of >1 µg/ml INH 
*
2 Low-level resistance: MIC between 0.1-1.0 µg/ml INH 
 
 
Table 1: Genes and gene mutations implicated in INH resistance per literature 
Locus associated with resistance Function Level of resistance 
ahpC-oxyR Intergenic Region Regulation of katG expression [41]. Resistant*1 [48] 
ahpC Involved in oxidative stress response [45] Low-level*2 [48] 
oxyR Compensatory under conditions of peroxide-induced stress [17] Resistant [48] 
furA Assists in catalase activity and INH susceptibility [49] Resistant [48] 
furA-katG Intergenic region Regulates transcription of katG [49] Resistant [49] 
fabG-inhA Regulatory region Alternative promoter for inhA [38] Resistant [50] 
inhA Involved in mycolic acid biosynthesis and resistance against 
isoniazid and ethionamide [24] 
Low-level [34] 
kasA Involved in fatty acid biosynthesis (mycolic acids synthesis) 
[17] 
Inconclusive [51] 
srmR homolog Unknown Inconclusive [44],[52] 
Ndh Transfer of electrons from NADH to the respiratory chain [50] Resistant [48] 
iniB Unknown Inconclusive [48],[53] 
iniA Unknown Inconclusive [53],[54]  
iniC Unknown Inconclusive [53],[54]  
Rv1592c Unknown Inconclusive [48] 
fadE24 Unknown Inconclusive [54]  
Rv1772 Unknown Inconclusive [54]  
efpA Translocation of the substrate across the membrane (efflux 
pump for antibiotic) [35] 
Inconclusive [52] 
fabD Malonyl CoA:ACP transacylase [17] Inconclusive [52] 
accD6 Involved in fatty acid biosynthesis (mycolic acids synthesis) 
[38] 
Inconclusive [48] 
mabA Fatty acid biosynthesis pathway [34] Low-level [36] 
katG Catalase-peroxidase activity that converts INH to its active 
form [50] 
Resistant [37] 
nhoA / nat Acetylation of INH (thereby inactivating it) [6] Inconclusive [48] 
embB Involved in the biosynthesis of the mycobacterial cell wall 
(synthesis of arabinogalactan) [8]  
Resistant [55] 
Rv0340 Unknown Inconclusive [53],[54]  
fbpC Mycolyltransferase activity required for the biogenesis of 
trehalose dimycolate (cord factor) [35] 
Inconclusive [48] 




 2b. Genes associated with high-level resistance 
i.  katG gene 
Mutations in the katG gene are the most common mechanisms associated with INH 
resistance in M. tuberculosis[35]. In addition, katG mutations confer medium to high-level 
resistance (minimum inhibitory concentration of > 1mg/ml) to INH[36],[37]. Taken together, 
these factors make katG mutations the most important mechanism of INH resistance. 
Mutations or deletions within the katG gene prevent the activation of INH upon its 
diffusion into M. tuberculosis, rendering INH ineffective against M. tuberculosis bacilli 
and resulting in high INH resistance levels[8],[36]. The catalase or peroxidase enzyme 
encoded for by the katG gene is often lost in highly resistant strains, however the catalase 
ability may be sustained in cases of low-level resistance caused by some katG mutations 
[8],[34],[38]. 
The majority of INH resistant isolates can be attributed to a katG mutation at codon 
position 315 where serine is substituted for a threonine [8],[31]. This information is important 
for diagnostic and treatment purposes because it has been shown that initial mono-
resistance to INH, specifically katG S315T mutations, often precede multi-drug resistance 
in M. tuberculosis [39]. Pym et al., 2002 showed in a mouse model that a resistant  katG 
S315T mutant produces active catalase-peroxidase and is virulent, revealing that a loss of 
bacterial fitness does not result from this frequent mutation[40]. Since M. tuberculosis is an 
aerobic organism, the catalase and peroxidase activity of katG is important for the 
breakdown of radicals that may cause cellular damage[34],[41].  
However, a whole genome study done by Torres et al. 2015, observed 14 alternative 
mutations in katG which were implicated in INH resistance[38]. Eight of these 
polymorphisms were novel (had not previously been associated with resistance). Thus, 
mutations at katG315 are common, but there are other katG mutations that may encode 
INH resistance and complicate resistance diagnoses. However, more work must be done to 
establish that resistance is truly owing to all the katG mutations in these isolates, and are 
not due to other INH resistance associated mechanisms. 
 




ii. kasA gene 
The role of kasA in mycolic acid synthesis is to elongate long chain fatty acids, which are 
essential precursor components of mycolic acid chains as discussed previously. Extension 
of these fatty acids via the FASII system occurs when an acyl carrier protein (ACP), 
alternatively referred to as InhA, binds to the active site of β-Ketoacyl synthase enzyme 
known as KAS (consisting of genes kasA and kasB)[42]. 
At this stage, we know that some polymorphisms in the kasA gene are present in certain M. 
tuberculosis sub-lineages and have no role in INH resistance, whilst others such as G961A, 
G805A, and G269S are found solely in INH resistant strains and are hypothesised to have a 
role in INH resistance[43]. However, it should be noted that the Jagielski study was not 
focused solely on kasA mutations and more work must be done on kasA before the tenuous 
link between the mutations and INH resistance can be confirmed or refuted. 
2c. Genes associated with low-level resistance 
i. inhA (mabA) promoter  
As InhA is the primary target for activated INH (the INH-NAD Adduct), mutations in the 
gene itself, or its promoter region (mabA-inhA operon) may disrupt this interaction and 
result in isoniazid resistant isolates[24],[34]. Extensive data shows that mutations or 
polymorphisms in the inhA promoter are the second most common explanation for INH 
resistance. More specifically, investigation of INH resistant isolates showed that a -15 
mutation in the inhA promoter was on average present in 19.5% of isolates from 49 
different countries[44]. Moreover, this mutation was seen in as many as 43% of INH 
resistant cases in specific geographical locations[44].  
It has been shown that M. tuberculosis strains with these mutations spread more rapidly 
than strains with other mutations[45],[46]. Specifically, Müller et al., 2011, showed that these 
isolates were more likely to acquire additional mutations, leading to XDR bacilli[46]. 
However, a key difference in INH resistance encoded by this gene in comparison to katG 
mutations, is that resistance is low-level (MIC of less than 1 mg/ml)[36]. This is due to the 
mechanism of resistance to INH i.e. upregulation of the target causes resistance by titration 
(the drug concentration is too low to block all the active sites available). Mutations in the 
inhA promoter have also been shown to confer cross-resistance to another pro-drug, 




ethionamide (ETH)[47]. ETH is activated by EthA to form an ETH-NAD Adduct that 
inactivates InhA, similar to activated INH[37]. However, in at least one documented case, 
the -15 C - T inhA promoter mutation was found to be present in isolates with high-level 
resistance to INH and ETH[37].  
Notably, while low-level resistance is conferred when each of these mutations occurs 
alone, this high-level resistance was present in all strains where simultaneous mutations in 
the inhA promoter region and inhA structural gene occurred,  implying a synergistic 
mechanism[37].  
Additionally, a study done by Ando et al. in 2014 discovered a non-synonymous mutation 
in the mabA gene at position 609 (glycine to alanine)[36]. This mutation was found in 
isolates that previously had no identifiable mechanism of resistance. Per that study, the 
mechanism of INH resistance associated with a mabA G609A mutation is to cause up 
regulation of inhA and to change the region adjacent to the mutation into an alternative 
promoter[36]. Thus this mutation is thought to confer INH resistance by causing 
overexpression of inhA in the same way that the canonical inhA promoter mutations do[36]. 
ii. inhA gene coding sequence 
Mutations in the inhA open reading frame of M. tuberculosis are not as common as in katG 
or inhA promoter but still occur often enough to be of interest[34]. If these mutations are 
present it is usually indicative of an M. tuberculosis strain with low-level resistance (MIC 
between 0.1-1.0 µg/L)[34],[55]. In particular, the S94A mutation in inhA decreases INH-NAD 
Adduct affinity for the NADH-binding site of InhA, therefore resulting in increased INH as 
well as ethionamide resistance[24].  
Other mutations in the inhA open ORF that have been implicated in INH resistance include 
mutations at position I21T/V, position A190S, position I194T  and at position I258T/V 
[24],[44].  
Due to the many different mutations in this region that have been associated with INH 
resistance, as well as the prevalence of mutations in this region being associated with low-
level INH resistance, it can be assumed that the inhA gene coding region is significant to 
INH action and resistance. 




iii. ndh gene 
The ndh gene encodes for a type II NADH dehydrogenase (NdhII). It is vital for the 
activation of INH upon its entry into M. tuberculosis cells and without it the INH-NAD 
Adduct cannot be formed [47]. A study by Vilchèze et al., showed for the first time that ndh 
gene mutations conferred a novel resistance pathway, and that these mutations conferred 
co-resistance to both isoniazid and ethionamide in Mycobacterium smegmatis (a fast 
grower) and Mycobacterium bovis BCG (a slow growing strain like M. tuberculosis)[47]. It 
was shown that the mechanism of this co-resistance in Mycobacterium bovis BCG was not 
due to overexpression of inhA, thus indicating that its mechanism was novel. All strains 
with a ndh mutation were found to have defective NdhII activity[47]. Due to the defective 
NdhII activity, the NADH/NAD+ ratios were increased intracellularly. It was hypothesised 
that this increased NADH/NAD+ ratio competitively inhibited the binding of the INH-
NAD Adduct to InhA thereby preventing its activation and effectively blocking the INH 
mechanism of action[47].  
A study done in Singapore in 2001 by Lee et al., discovered ndh mutations in INH resistant 
strains that were absent in all INH susceptible strains. Specifically, 8 out of 84 INH 
resistant isolates had ndh mutations, with 7 of these containing no additional mutations that 
have been implicated in INH resistance. Only one of the 8 had another mutation in addition 
to the ndh mutation and this was in the ahpC gene (which is not thought to confer 
resistance on its own)[56]. A further study by Viswanathan et al. 2016, confirmed the 
presence of ndhII mutations in INH resistant isolates from the above mentioned Singapore 
cohort[32]. The mutations in this study, as well as their association with INH resistance 
were validated by MIC determination and complementation studies with the corresponding 
M. smegmatis and M. tuberculosis genes[32]. Thus, this study confirmed that ndhII 
mutations confer INH resistance[32]. 
To add some perspective and more diverse epidemiological data, a 2006 study by 
Hernando Hazbon et al. worked with 1011 M. tuberculosis clinical isolates from Australia, 
Colombia, India, Mexico, New York, Spain, and Texas[34]. This study found mutations in 
the ndh gene (or its upstream regions) in 30 of these isolates. The most common ndh 
mutation, V18A, was detected in 28 isolates, but 16 were in INH susceptible strains and 12 
in resistant isolates. Alternatively, two resistant isolates had an R268H ndh mutation, 
which was not present in susceptible isolates. Thus, only two ndh mutations were present 




solely in INH resistant strains. This suggests that not all ndh polymorphisms are causative 
of INH resistance, and that epidemiologically, the role of those ndh mutations that do cause 
INH resistance, is minimal[34]. 
The interactome of the M. tuberculosis cell and INH is represented in Figure 1. It includes 
INH mechanism of action and diagrammatically shows how mutations within certain genes 
prevent INH from functioning effectively. Panel 1 shows the normal functioning of the 
FASII system (i.e. when INH is not present in the system). Alternatively, Panel 2 
diagrammatically presents the functioning of the FASII system in the presence of activated 
INH and thus displays the INH mechanism of action. Additionally, the INH point of entry 
into the cell is represented, to better visualise the formation of the INH-NAD Adduct. This 
modified INH targets and blocks InhA activity, thus blocking elongation of fatty acids 
within the FASII system of M. tuberculosis. The mutations represented Panel 3 are 
mutations in ndh, kasA, inhA and mabA promoter. In each case Panel 3 shows the effects 
of the mutations in these genes, i.e. which step of the FASII system is blocked. Of interest 
in the context of this review is how mutations in the mabA promoter region, inhA gene and 
ndh affect resistance. These genes are known to result in low-level INH resistance in M. 
tuberculosis. Low-level INH resistance, particularly in the presence of fast metabolism, 
could allow additional mutations, development of high-level resistance and progression to 















Key for Figure 1: 








Figure 1: Interactome of M. tuberculosis cell and INH. 
 
Panel 1: Normal functioning of FAS II system 
Panel 2: Interruption of FAS II system by activated INH 
Panel 3: Effect of mutations:  
• Mutation in mabA/promoter: upregulation of MabA and InhA  resistance by 
titration 
Panel 4: Effect of mutation: 
•  Mutation in katG: INH not activated 
Panel 5: Effect of mutation: 
•  Mutation in inhA gene: decreases INH-NAD adduct affinity for the NADH-
binding site of InhA  increased INH + ETH resistance 
Panel 6: Effect of mutation; 
•  Mutation in ndh: INH-NAD adduct cannot be formed  INH not activated 
 
 




2d. Gene associated with compensatory mechanism 
i. ahpC-oxyR Intergenic Region 
The ahpC-oxyR intergenic region is thought to be responsible for the regulation of katG 
expression[41]. Both the ahpC and oxyR genes are upregulated in M. tuberculosis under 
conditions of oxidative stress. The promoter region of ahpC tends to acquire mutations 
when katG is absent or mutated and there is no catalase or peroxidase activity[8]. Often in 
INH resistant strains that have a katG mutation, overexpression of the aphC gene is 
induced to compensate for the lack of catalase/peroxidase activity by providing an 
alternative mechanism for clearing reactive oxygen species. However, overexpression of 
AphC did not confer significant INH resistance, or at most low-level INH resistance[8]. 
The alkylhydroperoxide reductase enzyme, encoded by ahpC, performs the same function 
as the ahpC-oxyR intergenic region and can compensate for the absence of catalase and 
peroxidase activity should there be katG mutations or a gene deletion [8]. The oxyR gene 
activates katG expression when the latter gene is intact, while oxyR is upregulated in the 
absence of functional katG, indicating a negative feedback mechanism[41],[57]. Apart from 
the catalase-peroxidase enzyme encoded for by katG, the oxyR gene is considered the 
primary regulator of the peroxide stress responses in M. tuberculosis. This gene is 
activated by exposure to low dosages of hydrogen peroxide and expresses proteins that 
protect the cell against these oxidative stress conditions[41].  
Mutations in the alkyl hydroperoxide reductase (ahpC) promoter have been associated with 
strains of M. tuberculosis that are resistant to INH[34],[45]. These mutations are hypothesised 
to be compensatory as they are believed to assist strains with adjusting to oxidative stress 
caused by gene mutations. However, mutations in the ahpC promoter region are fairly rare 
and are usually found in conjunction with katG mutations or deletions[45]. 
3. Methods of testing for Isoniazid resistance and current 
treatment regimens 
Traditional methods to test for susceptibility to anti-tuberculosis drugs, such as INH, 
involve phenotypic tests. Examples of these currently in use include minimum inhibitory 
concentration (MIC) testing, or microscopic observation of drug susceptibility (MODS)[32].  




Measuring the MIC of an antibiotic against M. tuberculosis involves culturing M. 
tuberculosis strains on media containing serial dilutions of the antibiotic. The level of 
resistance is then determined by comparing the colony forming units (CFU’s) of a control 
plate without antibiotic, to the CFU’s of the plate with the lowest possible concentration 
where growth was completely inhibited[58]. However, phenotype testing using the MGIT 
960 instrument coupled with TB Exist software, allows for more accurate and considerably 
faster output times[11]. MIC testing is based on the simple principle that if M. tuberculosis 
is able to grow in the presence of an antibiotic, it must be resistant to the antibiotic at that 
concentration and all concentrations below[59].  
Lakshmi et al., noted in 2014 that M. tuberculosis isolates that were low-level resistant to 
INH were also more likely to be cross-resistant to ETH[60],[61]. The MIC testing method 
was used in that study to test for cross-resistance and the level of resistance. The authors 
concluded that this method (viz. MIC) was effective enough to classify the level of 
resistance of standard cases, but was less effective in diagnosing borderline INH resistant 
isolates. As such, it was concluded that a modified MIC method would be required to more 
accurately determine cases of low-level resistance and cross-resistance to ETH[60]. 
Thus, while phenotypic methods such as MIC testing and MODS are particularly useful in 
resource poor settings due to their low cost, they are labour intensive and time consuming 
because of the slow growth rate of M. tuberculosis. To reduce time-to-diagnosis, molecular 
methods have been developed and implemented. These methods function on a genotypic 
level to pinpoint mutations of the M. tuberculosis genome that are associated with drug 
resistance[32]. There is clear justification for this, since rapid identification of antibiotic 
resistance in M. tuberculosis is vital to ensure an effective and competent therapeutic 
regimen to limit the spread of multi-drug resistant strains[53]. 
As outlined earlier, isoniazid resistance occurs via genetic mutations primarily within 
specific regions of the M tuberculosis genome, such as katG or the inhA operon. According 
to Seifert et al., 2015, mutations in katG315 and inhA promoter -15, in addition to ten of 
the most commonly occurring mutations in the inhA promoter and the ahpC-
oxyR intergenic region explain 84% of global phenotypic isoniazid resistance[44]. In order 
for molecular–based drug susceptibility testing (DST) methods to achieve 100% sensitivity 
and specificity, all of the genes that confer INH resistance must be identified, classified, 
and characterised in terms of severity (level of resistance)[62]. 




Since mutations in katG, inhA, kasA and the oxyR-ahpC intergenic region are most often 
associated with INH resistance, these are obvious targets for diagnostics. The katG 315 
codon is a prominent target, since it encodes high- level resistance and mutations often 
precede multi-drug resistance in M. tuberculosis.  
The Line Probe Assay (LPA) MTBDRplus is a molecular method that can partially achieve 
this, as it screens for mutations in the katG and inhA promoter which are known to be 
associated with INH resistance[32],[63],[64] The LPA method involves isolating bacterial 
DNA from the M. tuberculosis isolate, amplifying the DNA via PCR and then observing 
the hybridisation to a probe with a biotin-labelled tag. If the probe is bound, a band, part of 
a “barcode”, will be visible. Probes on the MTBDRplus are designed to indicate the 
presence or absence of M. tuberculosis, INH resistance and rifampicin (RIF) 
resistance[65],[66].  
The LPA tests specifically for mutations in katG 315 (S315T1 and S315T2) as these 
mutations are most commonly associated with resistance to INH[8], as well as -15 (C15T), -
16 (A16G) and -8 (T8C/ T8A) mutations in the inhA promoter[66]. Thus, any mutations that 
cause INH resistance, but occur outside of these specific regions will be missed by the 
LPA, thereby misclassifying the patient as INH susceptible.  
In routine laboratories in South Africa, INH resistance in M. tuberculosis isolates is 
determined by means of Hain GenoType MTBDRplus. However, if this method predicted 
INH susceptibility and the isolate is RIF resistant, a second specimen will be tested by 
culture-based DST for INH. It is important to note that for INH resistance, the sensitivity 
of the MTBDRplus assay, compared to conventional drug susceptibility testing, was found 
to be 90%, although the LPA has a better positive predictive value for RIF resistance 
compared to INH resistance[53],[67]. This disparity is likely due to the restricted number of 
RIF resistance causing mutations, which are mostly detected by the LPA, compared to the 
diversity of INH resistance causing mutations.  
Furthermore, it has been observed[53], that the LPA is not 100% effective in detecting 
mutations in the limited number of targets included on the LPA. However, it should be 
noted that this may be due to the test being incorrectly used[63].  
The LPA is also not an effective means of diagnosing resistance when heteroresistance or 
mixed infections occur. The resultant outcome will be dependent on the proportion of the 




mix of susceptible and resistant strains, favouring the more common strain. For example, 
the patient could be incorrectly diagnosed as having an INH susceptible strain of M. 
tuberculosis, should the resistant strain be a minor component of bacterial burden at time 
of diagnosis, and the incorrect drug treatment regimen would be prescribed[67]. 
A comprehensive study by Brossier et al., from 2006 suggests that the current systems in 
place in routine laboratories enables the detection of approximately 89% of the INH-
resistant strains with high-level resistance but only 17% of the strains characterized by 
low-level INH resistance[53].  
4. Host based INH metabolism 
Quite apart from any metabolic pathways in M. tuberculosis, INH is also metabolised by 
the human host by arylamine N-acetyltransferase (NAT). This enzyme is a polymorphic 
drug-metabolising enzyme, of which there are two isoenzymes, NAT1 and NAT2 in 
humans[28]. NAT1 acetylates p-aminosalicylate (PAS), however of interest in the context of 
this review is arylamine N-acetyltransferase 2 (NAT2), which occurs mainly in the liver 
and gut of humans. In the context of the human host, the effectivity of the INH drug (i.e. 
treatment outcome) partly depends on the metabolic rate of N-acetyltransferase[6]. As stated 
earlier, once acetylated, INH cannot be activated by the microbial catalase-peroxidase 
complex to the active form. This highly polymorphic gene and its effects have been 
extensively studied and phenotypes and their reaction to INH therapy will be discussed 
more in depth later.  
Xenobiotic molecules are metabolised by living organisms via a variety of enzymes. 
Metabolic rates may be dependent on several factors, such as ethnicity, body weight, HIV 
status, etc.[6],[9]. However, in humans, arguably the most important metabolic activity 
pertaining to INH is acetylation, mediated by N-acetyltransferase[6]. Once acetylated, INH 
is rendered ineffective as an antibiotic against M. tuberculosis. The genes for NAT2 are 
highly polymorphic[68], but essentially the alleles encode either a fast or slow-acting form 
of the enzyme. Thus, depending on homozygous or heterozygous state, an individual can 
be classified as a fast, intermediate or slow phenotype for INH acetylation, as alleles are 
co-dominant[68]. Fast-acetylation of INH may result in low serum concentrations of the 
anti-tuberculosis drug, consequently resulting in a higher risk for treatment failure[6],[43]. 




Conversely, slow-acetylators are at higher risk for INH-induced hepatotoxicity[6],[43]. This 
INH hepatotoxicity is due to oxidative stress mediated by hepatic CYP2E1[69]. INH is 
metabolized by NAT2, largely in the liver of the human host, to acetyl-INH via the 
primary metabolic pathway of INH, which is then hydrolysed to acetyl hydrazine. Acetyl 
hydrazine can be oxidized by cytochrome P450IIE1 (CYP2E1) to form N-hydroxy acetyl 
hydrazine, which is known to yield reactive hepatotoxins in slow-acetylators of INH. This 
includes acetyldiazene (or its products such as the reactive acetyl onium ion), acetyl 
radicals and ketene, which can bind covalently with hepatic macromolecules and result in 
liver damage[69].  
Thus, a single standard dosage of INH poses a risk of adverse events for slow-acetylators 
and risk of treatment failure for fast-acetylators. 
5. Factors that influence treatment outcome 
Low-level resistance to INH has been associated with failure of tuberculosis treatment 
therapy or relapse[67], as antibiotics will only act effectively if concentrations are above the 
MIC for M. tuberculosis and are adequately maintained (adequate area under the curve or 
“AUC”).  
For TB treatment, resistance to INH is commonly defined by an MIC of >1ug/L. However, 
this is a somewhat arbitrary definition, since there is no binary outcome for resistance, such 
that the bacilli are either fully susceptible to INH or resistant at MIC>1ug/L. In South 
Africa, for example, it was reported that the MICs of INH for approximately 50% of the 
INH resistant organisms studied were in the low-level resistance category, where low-level 
resistance to INH is characterised by an MIC between 0.1-1.0 µg/L[68]. As a result of serum 
levels of INH using current therapeutic dosage exceeding this level of resistance, 
particularly shortly after dosing[36], we may initially predict that low-level resistance is 
irrelevant. However, in the context of fast metabolism of INH, re-evaluation may be 
required. 
With respect to antibiotic therapy, the AUC and minimum inhibitory concentration (MIC) 
represent the parameters with the best correlation to possible clinical outcomes[69]. 
However, to assume that all patients will react the same is not in the best interest of 
patients. INH elimination in humans is trimodal (slow, intermediate and fast-acetylators) 
and substantially different half-lives of INH are experienced[9],[66]. In the fast-acetylator 




































INH concentration as a function of time 
after an oral dose of 10 mg/kg
high/intermediate level fast
intermediate slow
(see Figure 2), INH concentration rises after administration and then declines to reach the 
critical concentration of 1ug/L after only 4,5 hours, in contrast to the slow-acetylator where 
decline to serum concentration of 1ug/L is reached only after 14,5 hours.  
From this we may conclude that in the case of patients receiving daily treatment and 
infected by a low-level INH resistant strain, effective INH concentration is present for only 
17% of the time in fast-acetylators, whereas slow-acetylators experience effective dosage 
for approximately 60% of the time, or more than 4-fold longer.  
Figure 2: Concentration time curve of INH after an oral dose of 10mg/kg. The black line 
represents a slow-acetylator, dark grey represents an intermediate-acetylator and the light 
grey represents a fast-acetylator. High/ intermediate resistance (MIC of > 1µg/ml to INH) 
is represented by everything above the coarse-dashed line and low-level resistance (MIC 
0.1-1.0 µg/L) is represented by the space between the dashed lines. Adapted from Parkin et 
al; 1997[69]. 
INH dosing based on the NAT2 genotype (slow, intermediate or fast-acetylators) may help 
to maintain patients within the therapeutic range required for INH to combat M. 
tuberculosis effectively irrespective of whether they have low-level resistant strains of M. 




tuberculosis. This approach would minimize treatment failures in fast- acetylators, 
particularly those with low-level resistant strains and reduce adverse events such as drug 
induced hepatoxicity in slow-acetylators.  
Moodley et al., (2014) did a study in mice to assess whether higher doses of isoniazid may 
be active against drug resistant TB, particularly in cases of low-level resistance to INH[70] . 
Note that this study considered the effectivity of INH based on the MIC only, and not on 
the rate of acetylation[70]. Approximately 50% of the INH resistant organisms were low-
level resistant in this study. The data suggests that high doses of INH may be a viable 
treatment option for cases of low-level INH resistance in patients[70].  
Although Burhan et al. (2013) reported that most TB patients with low serum level INH 
and fast-acetylation had good treatment outcomes on a first-line antibiotic multi-drug 
regimen, this study excluded patients with any resistant isolates and did not report on 
longer term follow up to assess whether mono-resistance had developed or relapse 
occurred[71]. Of these patients, 1% failed to be cured and patients with a “poor” response 
had very low plasma antibiotic levels (in this case “poor response” is defined as at least 
one positive culture at week 4, 8, or 24/32). Others[72], have shown that in cases where low-
level resistance exists, a portion of the bacillary population may survive the initial 
exposure to INH during treatment. Curiously, Burhan et al (2013) reported that several 
patients with low serum antibiotic concentration that had a negative culture at week 4 or 8, 
presented with a positive culture at weeks 8, 24 or 32[71]. This study had no longer term 
follow up, so it is not evident whether these were forerunners of resistance development or 
relapse. However, it is important to note, follow-up would not necessarily show acquisition 
or relapse. More intensive molecular typing would be required for that, and it may even be 
possible to tell from the existing time-points. It was  shown  years ago,[73] that slow-
acetylators responded well to the conventional doses of INH (namely, 3-5 mg. INH/Kg. 
/day), but that fast-acetylators would potentially require higher doses of INH (up to 
32mg./Kg. of body weight/day).   
Van Deun et al. 2010 justify high-dosage INH as a supplement to 9 months of treatment 
with gatifloxacin, clofazimine, ethambutol, and pyrazinamide[74]. This intensive phase 
supplement of high-dose INH (in addition to prothionamide and kanamycin) for a 
minimum of 4 months resulted in a relapse free cure in 87,9% of patients in Bangladesh. 
Alternatively, a regimen lacking INH was shown to result in much lower effectiveness 




(57,1% cure). Thus, the results of this study suggest that high-dose INH plays a vital role 
in treatment of MDR-TB[74]. In this study, MIC determination was not done and thus 
treatment was not individualised. We suggest that targeted treatment would yield even 
better outcomes. A similar conclusion was reached by an independent study[75], i.e. that 
high dose INH can be effective in the presence of the inhA gene mutations. 
The failure to take a personalised dosage and diagnosis of low-level resistance into use has 
at least two negative consequences: firstly, there is the risk that patients will not respond to 
treatment optimally, particularly during the 4-month extension phase when only 2 
antibiotics (viz INH and RIF) are given. Secondly, and perhaps more importantly from a 
programmatic point of view, there is the risk of development of antibiotic resistance. Our 
own studies have shown that low-level INH resistance, as defined by mutations in the inhA 
promoter, are more common than mutations in katG in certain South African 
settings[46],[76]. This data suggests that such mutations conferring low-level resistance (and 
simultaneously including resistance to ETH) are a gateway to the development of further 
resistance, including high-level INH resistance, encoded by “classical” katG mutations that 
confer high-level resistance to INH[72].  
Unfortunately, our knowledge of INH resistant strains and whether tailored INH treatment 
regimens will provide improved outcomes and reduce generation of antibiotic resistance, is 
limited. We do not advocate substitution of INH currently, due to its low cost and its 
general effectiveness. However, we believe we have the ability to make the use of INH 
more effectively with our current understanding of the mechanisms of action and 
metabolism of INH[10] . This is particularly important in view of the ease with which M. 
tuberculosis can acquire first low-level, and subsequently high-level resistance to 











We suggest that low-level INH resistance, in the presence of fast-acetylation, is an 
underrated component of the global TB epidemic worldwide, and may be a significant 
problem in terms of treatment outcome and progression to antibiotic resistance. In 
combination, these two factors can be a generator of mono-antibiotic (isoniazid) resistance, 
eventually leading to progression to multi-drug resistance [46],[76]. We need to investigate 
this carefully and test whether personalised diagnostics and targeted high dose treatment 
with INH will reduce the incidence of isoniazid mono-resistant and multi-drug resistant 
(MDR) tuberculosis. Since we have shown that serum concentrations of INH can drop well 
below MIC, particularly in the case of fast-acetylators, we should arguably also rethink the 
intermittent (5 days a week) therapy widely employed in first-line TB treatment. Although 
this program saves on costs, it has been associated with relapse and acquired drug 
resistance [77]. The World Health Organization (WHO) recommended in 2008 that daily 
regimens be employed as the preferred dosing schedule for TB [77], however intermittent 
regimens are still an option in several national TB guidelines [78], which is not ideal.  
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3.1  Introduction and Summary 
In this study we investigated the reasons for discrepant isoniazid (INH) resistance results in 
isolates that were sent to the National Health Laboratory Services (NHLS) Port Elizabeth 
for routine diagnosis. Standardized methods were used to elucidate the mechanisms of INH 
resistance for samples from NHLS with discrepant status. These procedures include 
Minimum Inhibitory Concentration (MIC), Sanger sequencing, Whole Genome 
Sequencing (WGS), spoligotyping and homologous recombineering. The experimental 
procedure is outlined below in Figure 3. 
 
 
Figure 3: Summary of techniques used in this study. 
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3.1.1 Ethics approval 
Ethical approval was obtained from the University of Stellenbosch Health Research Ethics 
Committee - reference number N09-11-296.  
3.2  M. tuberculosis sample selection 
The mechanisms of INH resistance were analyzed in 397 M. tuberculosis isolates obtained 
from the NHLS Port Elizabeth with discrepant status. These samples were collected 
between June 2014 and May 2016 from the Eastern Cape Province and were found to be 
susceptible to INH by a routine molecular diagnostic test, the Hain GenoType 
MTBDRplus LPA[1], but subsequent phenotypic drug-susceptibility testing (DST) on 
MGIT960 classified them as resistant to INH. The samples in this dataset were selected 
based on their discrepant status. 
3.3  MIC determination 
MIC determination was done according to the method described by Sirgel et al. in 2009[2]. 
The MIC of INH was determined using the BACTECTM MGIT 960TM system[3] to confirm 
drug resistance.  
The BACTECTM MGIT 960 is used for rapid qualitative susceptibility testing of anti-
tuberculosis drugs. MGIT tubes contain an oxygen-quenched fluorochrome, tris 4, 7-
diphenyl-1, 10-phenonthroline ruthenium chloride pentahydrate, embedded in silicone at 
the bottom of the tube. The free oxygen in the medium is utilized by bacterial growth and 
replaced with carbon dioxide. Depletion of free oxygen results in fluorescence of the 
oxygen sensor in the MGIT tubes when exposed to UV light. The intensity of fluorescence 
is directly proportional to the extent of oxygen depletion and thus bacterial growth. 
Typically, qualitative susceptibility testing is dependent on growth reaching the critical 
concentration as a standard, to differentiate between susceptible and resistant strains of M. 
tuberculosis to INH. However, due to the specifications of this study, the level of 
resistance to the drug was additionally determined quantitatively via extended individual 
drug susceptibility testing (exposure to different drug concentrations). 




The BACTECTM MIGIT method for DST is based on proportionality. The MGIT 
determines susceptibility by comparing growth of the test isolate at a standard inoculum 
size and in the presence of an antimicrobial to that in a drug-free control (growth control, 
GC) with a 1/100 diluted inoculum to represent 1% of the standard inoculum size. A 
resistant strain shows better growth in the presence of an antimicrobial as opposed to the 
GC. More growth in the GC as compared to the drug-containing test tube indicates that 
more than 99% of the bacterial population has been inhibited and the isolate is therefore 
considered susceptible. Thus, the bacterial population is considered to be resistant when 
1% or more of the population is resistant to the test drug – in this case INH. 
In the MGIT system, low-level resistance to INH is when there is growth between 0.1 and 
1 µg/ml INH. High-level resistant status is designated to a sample if there is growth at 
concentrations higher than 1 µg/ml INH.  
The reagents used for this method can be found in the Supplementary data. The storage 
of bacterial strains was done by centrifuging strains of M. tuberculosis grown in liquid 
Middlebrook 7H9 medium, at 3000 x g for 15 min. Next, the pellets were resuspended in 
glycerol peptone water medium and vortexed for 30 secs. Sterile glass beads (diameter of 4 
mm) were covered with the suspension and preserved in Nunc vials at -70°C to -80°C.  
To subculture from frozen cultures, the MGIT tubes were labelled with the specimen 
number and 0.8 ml of reconstituted OADC growth supplement was added aseptically to 
each MGIT tube. For each isolate, a single glass bead coated with M. tuberculosis and 
stored at -70°C was then removed from Nunc vials, under sterile conditions, and added to 
MGIT tubes labeled with corresponding specimen numbers. Thawing of remaining vials 
was prevented by keeping it on dry ice and by returning it to a -70°C freezer as soon as 
possible. The inoculated tubes were mixed well, scanned and placed into the BACTECTM 
MGIT 960 instrument. The tubes were then incubated at 37°C until the instrument flagged 
them as positive.  
Subsequently, 0.5 ml of sub-culture was transferred from tubes into the freshly prepared 
MGIT tube and incubated at 37°C. It is important to note that the day the MGIT tube 
became positive, is considered Day 0, after which the sub-culture was incubated for at least 
one more day (Day 1) before using it as inoculum for susceptibility testing.  A positive 
tube was used for drug susceptibility testing up to and including the 5th day (Day 5) after it 




became instrument positive. Cultures were thoroughly mixed through inversion or 
vortexing. The undiluted suspension was then used for inoculation of drug sets. 
Subcultures of clinical isolates with discrepant status were grown at 4 different 
concentrations of INH to determine the level of resistance. These isolates were grown in 
the presence of INH at concentrations of 0.1, 1, 5 and 10 µg/ml and a no drug control was 
included. For each sample an aliquot of the no growth control, an aliquot of lowest 
concentration at which growth occurred (referred to in workflow as “drug tube”) as well as 
a crude DNA aliquot of the original sample were made. The purpose of the no growth 
control is to serve as reference for a concentration of INH that M. tuberculosis is not 
resistant to and the drug tube is determinant of the level of resistance to INH. Thus, 3 tubes 
were obtained per clinical isolate via MIC, and these tubes were subsequently used for 
spoligotyping, Sanger sequencing and Whole Genome Sequencing (WGS). Figure 4 below 
describes the workflow employed for each clinical isolate obtained from NHLS Port 
Elizabeth. 
 
Figure 4: Schematic representation of method employed for MIC determination.  
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3.4  Strain typing 
All 397 clinical isolates that formed part of this study were genotyped by spoligotyping 
according to the method described by Kamerbeek et al. in 1997[4]. It was done to classify 
the isolates in strain families and to detect the presence of mixed infections.  
Spoligotyping is an internationally standardised reverse line probe assay based on the 
direct repeat (DR) region of M. tuberculosis, which consists of direct repeat sequences 
with unique spacer sequences that have been extensively studied in TB research[5]. This 
method is simple and has allowed the organization of the isolates of this study into strain 
families in accordance with the international spoligotype database[6]. 
Briefly, the 3 tubes per sample (original sample, growth control and drug tube) obtained in 
method a) were amplified via PCR. The PCR mix used for amplification is summarised in 
Table 2 and the PCR cycles in Table 3 
Table 2: PCR mix for amplification of DNA for genotyping 
PCR mix 25 µl 
ddH2O 6.5 µl 
Kapa Taq readymix[7] 12.5 µl 
DRa[8] 2 µl 
DRb[8] 2 µl 
DNA template 2 µl 
 
Table 3: PCR cycles for spoligotyping 
Temperature  Time  Step 
95˚C 3 min Activation 
94˚C 1 min Denature 
55˚C 1 min Annealing 
72˚C 30 sec Extension 
72˚C 10 min Final Extension 
 
x30 (can vary from 28 
to 35 cycles) 




The solutions used can be found in Supplementary data. After amplification, 20 µl of 
PCR products was added to 150 µl 2x saline sodium phosphate ethylene diamine tetra-
acetic acid EDTA/SSPE 0.1% sodium dodecyl sulphate (SDS). Next, the products were 
heat denatured at 99ºC for 10 minutes and immediately cooled on ice to prevent re-
annealing of the single DNA strands. The membrane was washed at 60˚C in 2xSSPE/0.1% 
for 5 min and then placed on a support cushion on the miniblotter[9] with the slots 
perpendicular to the line pattern. Residual fluid was removed from the slots via aspiration 
and the slots were each filled with 150 µl diluted denatured PCR product and care was 
taken to avoid air bubbles. Hybridization occurred at 60˚C for 60 min on a horizontal 
surface. Next, the samples were removed from the miniblotter via aspiration. The 
membrane was washed twice in 2xSSPE/0.5%SDS for 5-10 min at 60˚C. Subsequently, 50 
ml 2xSSPE/0.5%SDS (42˚C) with 12.5 µl Strepdavidine-peroxidase conjugate (500U/ml) 
was added and incubated at 42 ˚C for 45-60 min. After this, the membrane was washed 
twice with 2xSSPE/0.5%SDS at 42˚C˚C for 5-10 min. Next the membrane was rinsed with 
2xSSPE for 5 min at room temperature and then incubated in 20 ml (10 ml solution 1 + 
solution 2) ECL mix[10] for 1 min 30 sec. The membrane was then exposed to film on X-
ray after 5-20 min exposure time with a hyperprocessor[10]. Lastly the membrane was 
stripped for re-use by washing in 1%SDS at 80˚C for 30 min-1 hour and then storing at 
4˚C in 20 mM EDTA pH8 overnight. 
 3.5 Sequencing of inhA promoter and katG 
3.5.1 Primer design for Standard Hotstart PCR reactions 
PCR primers for amplification of genes of interest were designed against the whole 
genome sequence of the M. tuberculosis H37Rv reference strain[11] using Primer 3 









Table 4: Primers used for PCR amplification 
Gene 





katG RTB 59 TGGCCGCGGCGGTCGACATT 
62ºC 419 bp [13] 




59ºC 282 bp This study 
inhAPrev ACATTCGACGCCAAACAGCC 
New primers were designed for this study to amplify inhA promoter. This was done to 
increase the Tm of inhA promoter to that of katG so that PCR amplification can be done 
for both genes simultaneously. 
3.5.2 Standard Hotstart PCR  
DNA from the above mentioned samples (3 per isolate) were subjected to  standard hotstart 
PCR reactions on the Applied Biosystems thermal cycler 2720 – to amplify the katG gene 
and inhA promoter region, followed by Sanger sequencing. The PCR mix[14] used for 
amplification is detailed in Table 5 and the PCR cycles in Table 6. 
Table 5: PCR mix for amplification of DNA for Standard Hotstart PCR 
Total mix 25 µl 
H2O 9.375 µl 
Q solution  5 µl 
10x buffer  2.5 µl 
MgCl2  2 µl 
dNTPs  4 µl 
Primer mix (2 primers)  1 µl 
Syto 9[15] 1 µl 
Qiagen Hotstart Taq[15] 0.125 µl 
DNA 1 µl 





Table 6: PCR cycles for Hotstart 
 
After PCR, confirmation of amplification was performed by High Resolution Melt (HRM) 
on the Rotor Gene 6000[15]. HRM analysis is molecular technique used for detection of 
genetic alterations related to drug resistance in M. tuberculosis. The DNA amplified via 
PCR is melted and the genetic alterations are detected according to the dissociation 
profile[16]. Amplification was judged to have occurred based on a melt curve. All PCR 
products that showed amplification were then Sanger sequenced on the ABI PRISM DNA 
sequencer model 377[17] at the Central Analytical Facility (CAF) of Stellenbosch 
University. 
The Sanger sequences of the katG and inhA promoter of each clinical isolate were then 
analysed using Bioedit[18]. This was done with the purpose of looking for specific 
mutations in these regions that could potentially be associated with INH resistance. 
However, several isolates had no detectable mutations in these regions and were 
subsequently selected for Whole Genome Sequencing to detect mutations that could 
potentially exist elsewhere in the genome. 
3.6  Sequencing katG 
DNA from the samples with no detectable mutation in the region of inhA promoter or katG 
Sanger sequenced in section 3.5 had the rest of katG amplified via a PCR reaction – the 
katG gene region was split into 3 fragments (namely fragment 4, fragment 3 and fragment 
1). These fragments exclude “fragment 2” around the katG 315 region that was amplified 
Temperature  Time  Step 
95˚C 15 min Activation 
94˚C 1 min Denature 
55˚C 1 min Annealing 
72˚C 1 min Extension 
72˚C 10 min Final Extension 
x40 




in section 3.6. The four different fragments of katG amplified in this study, as well as their 
relevant positions within the gene, are presented diagrammatically in Figure 5. 
Figure 5. Four fragments of katG amplified via Sanger sequencing in this study (1)-(4), 
where relevant fragment size is indicated prior to “bp” and numbers above square brackets 
indicate relative genetic position. 
3.6.1 Primer design for Standard Hotstart PCR reactions (rest of 
katG) 
PCR primers for amplification of three fractions of the gene of interest were designed 
against the whole genome sequence of the M. tuberculosis H37Rv reference strain [11] 
using Primer software 3 version 0.2[12]. The primers used in this study are detailed in Table 
7. 
Table 7: Primers used for PCR amplification of rest of katG 
Gene 















62ºC 819 bp This study 
katG3R TTCGCCTTGTCGAGCAGCAT 








62ºC 587 bp This study 
katG4F GCTGGCCACAACATCACGG 
 
Specialized primers were designed for the PCR reaction as there were no established 
primers in the literature. 
3.6.2 Standard Hotstart PCR for rest of katG 
DNA from the samples with no canonical mutation in katG or inhA promoter in section 3.5 
were subjected to a hotstart PCR reaction on the Applied Biosystems thermal cycler 2720 – 
to amplify the rest of the katG gene. This was followed by Sanger sequencing. The PCR 
mix[14] used for amplification is summarised in Table 5 and the PCR cycles in Table 6. 
Qiagen Hotstart taq was used and 1 µl Syto9[15] was added in addition to the standard PCR 
mix as fluorescence for detection by the High-Resolution Melt (HRM) experiments on the 
Rotor Gene 6000[15], as described in section 3.5.All PCR products that showed 
amplification were then Sanger sequenced on the ABI PRISM DNA sequencer model 
377[17] at the Central Analytical Facility (CAF) of Stellenbosch University. 
The Sanger sequences of katG of each clinical isolate were then analysed using Bioedit [18]. 
This was done with the purpose of looking for specific mutations in these regions that 
could potentially be associated with INH resistance. However, several isolates had no 
detectable mutations in these regions and were subsequently selected for Whole Genome 
Sequencing to detect mutations that could potentially exist elsewhere in the genome. 
 
 




3.7  DNA isolation and Whole Genome Sequencing 
3.7.1 DNA isolation 
Isolates of M. tuberculosis with no elucidated mechanism of resistance were cultured on 
7H11 solid media for DNA extraction. Cultures on 7H11 plates were heat inactivated at 
80˚C for 2 hours and lysozyme powder [19] was brought to room temperature. During the 
waiting period, the conical bottom of a 50 ml BD Falcon tube was filled with 5 mm glass 
beads and 6 ml extraction buffer (which consists of Mono Sodium Glutamic Acid (MSG), 
Tris, EDTA and hydrochloric acid) was added. After the cultures were heat inactivated, the 
confluent growth (usually from 2 plates) was scraped into tubes and the tubes were then 
placed in a vortex for 2 minutes until a milky consistency was achieved. Next, enough 
lysozyme for the plates (+ 1ml extra) was reconstituted by making use of a 100 mg/ml 
working concentration. A volume of 500 µl was added per tube and mixed by inversion in 
order to obtain a homogenous mixture. The tubes were then incubated at 37˚C for 2 hours. 
After the specified time, 600 µl proteinase K buffer[19] and 300 µl proteinase K[19] 
(10mg/ml) were added to the tubes and they were incubated at 45˚C overnight. The next 
day PCI (Phenol[19], chloroform[19], isoamylalcohol[19]; in proportion 25:24:1) was poured 
into a flask. After phase separation occurred, 5 ml PCI from the bottom layer was added to 
each tube of culture. Each tube was inverted every 30 min for 2 hours at room temperature 
in the fume hood. Next, the tubes were centrifuged at 3000 rpm for 20 min at room 
temperature (21˚C). From these tubes 5ml CI (chloroform/isoamylalcohol; 24:1) was put 
into new 50 ml tubes and the top layer PCI was aspirated with a 5ml pipette and added to 
CI. The new tubes were then inverted and centrifuged at 3000 rpm for 20 min at room 
temperature. We placed 600 µl sodium-acetate (Na-Ac; 3M) [19] in new 50 ml Falcon tubes 
and aspirated the top phase to the Na-Ac tubes. Following this, 2 rows of 1.5ml Eppendorf 
tubes were packed. The first row contained 1ml 70% ethanol in each tube and the second 
tube was empty. We added 7ml ice-cold isopropanol to the Falcon tubes and they were 
gently inverted until precipitated DNA could be observed. The DNA was then immediately 
fished with a glass rod. The rods covered in fished DNA were in placed in the ethanol 
Eppendorf tubes and the second row tubes of empty Eppendorf tubes with their glass rods 
were labeled. After 10 min the rods with DNA were placed in empty Eppendorf tubes and 
left to dry at room temperature. Once dry, 300 µl TE buffer (Sigma - Aldrich) was added to 




the tubes, left for 5 min and the rods were removed while gently stirring to leave the DNA 
behind. The DNA was incubated at 4˚C overnight or alternatively, 65˚C for 2 hours. The 
isolated DNA was stored at -20˚C until use in further experiments. 
3.8  Whole Genome Sequencing 
Whole genome sequencing was done in collaboration with CDC in Atlanta, GA. Library 
preparation was done by making use of 1 µg of genomic DNA per sample. DNA was 
fragmented to an average length of 600 bp (focused ultrasonicator, Covaris LE220), and 
samples underwent size selection via 0.6X AMPure XP bead purification. Library 
preparation was completed as per the manufacturer’s recommendation using the NEBNext 
Ultra DNA library prep kit for Illumina (New England BioLabs) with dual indices. 
Samples were pooled to a final loading concentration of 1 pM and sequenced on an 
Illumina NextSeq 550 platform using the 500/550 mid-output v2 (300 cycle) kit. 
3.8.1  Bioinformatic analysis of WGS data 
In order to analyse the WGS sequenced reads obtained, an in-house tool was used. The 
universal sequence analysis pipeline (USAP) - developed by the bioinformatics team at 
University Stellenbosch – consists of several software packages and python scripts in order 
to optimally extrapolate bioinformatics data. The reference sequence used was M. 
tuberculosis H37Rv (accession number: AL123456.3). The work flow is diagrammatically 
summarised in Figure 6. 






Figure 6: Work-flow employed for bioinformatic analysis of Illumina WGS reads to 
elucidate novel mechanisms of resistance to INH. 
 




3.8.2 Quality Assessment 
To assess the quality of the raw sequencing reads, each isolate was analysed using the 
FastQC program (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC is 
a java script with a HTML output format[20]. The purpose of this program is to interpret 
sequencing quality based on the FastQ files that were sequenced on the Illumina platform. 
The FastQ files are analysed with several modules in order to extrapolate data relating to 
basic statistics, mean quality scores overall as well as reads per base position, distribution 
of read lengths, the distribution of uncalled bases, level of duplication in reads and 
identification of individual reads that may have a bias due to overrepresentation. 
3.8.3 Computational Analysis 
The FastQ files of isolates that passed the quality assessment were put through a WGS 
pipeline named USAP. USAP amalgamates a variety of software packages and utilises 
open source WGS analysis tools in conjunction with customised scripts to filter and 
annotate reads[21]. 
Trimming of reads 
Trimmomatic[22] was used to remove low quality bases, duplicates and adapters with a Q 
value obtained via the Illumina platform, and a cut off value of 36 bp for the minimal read 
length[23]. Thus taking into consideration coverage, target length and error rate. 
Alignment to a reference genome 
The remaining high-quality reads were aligned to the M. tuberculosis H37Rv reference 
genome with three different alignment tools:  
1) Burrows-Wheeler Aligner (BWA)[24] (http://bio-bwa.sourceforge.net/), 
2) NovoAlign[25] (Novocraft - http://www.novocraft.com/products/novoalign/)  
3) SMALT[26] (http://www.sanger.ac.uk/science/tools/smalt-0). 
The Sequence Alignment/Map (SAM) file output format[27] , is a version of the alignment 
that improves the ability to work with it in the following steps. 
 




SAM file conversion, validation and indexing 
The “ValidateSamFile.jar” command of the Java based Picard Tools program 
(https://broadinstitute.github.io/picard/) was used to validate the obtained SAM files. The 
SAM files were converted into their binary (BAM) file format, using the “view” and “sort” 
command of SAMTools[27] (https://github.com/samtools/bcftools/releases/download/), 
followed by the “index” command, to simplify the processing steps for the next programs 
and create the indexed BAM (BAI) file. 
Alignment statistics and realignment of BAM files 
Specifics about the total number of input reads for the alignment, the number of duplicated, 
mapped and mate paired (associated at the same locus in the BAM file)  reads were 
generated in a text file (txt) format with SAMTools “flagstat” command[28]. The java based 
Genome Analysis Toolkit (GATK) (https://software.broadinstitute.org/gatk/) was used to 
re-align the sequence reads around InDels, following the best practices recommendation. 
An interval file was generated from the BAM file format using the 
“RealignerTargetCreator” command, in order to be able to realign around small InDels, for 
which the GATK “IndelRealigner” command was used[28]. 
Removal of PCR duplicates 
Thereafter, BAM files were re-sorted with the java based Picard Tools 
(http://broadinstitute.github.io/picard/) command “SortSam.jar”, re-indexed with the 
“index” command from SAMTools, followed by the identification and removal of any 
PCR duplicates with the “MarkDuplicates.jar” command from Picard. 
3.8.4 Validation of Variants 
Variant calling 
Single nucleotide polymorphisms (SNPs) and InDels were identified with the “mpileup” 
SAMTools command and the GATK[28] “UnifiedGenotyper” tool. Information about the 
variant positions, the phred (base calling program for DNA sequence traces to assess their 
quality) scaled probability and the alternative sequence are given in the obtained variant 
calling format (vcf) files[29] , which were used for further variant comparisons. 




Annotation and functional classification of SNPs/InDels 
High confidence SNPs and InDels were identified with the triplicate of mappers (BWA, 
Novoalign, SMALT) covered by more than 30% of the average depth of coverage of the 
reads and had a heterogeneity frequency of more than 0.8. They were annotated and if 
applicable, the consequent amino acid change, or effect on the reading frame of 
corresponding genes were calculated with a python script included in USAP. 
Genome coverage 
The genome coverage was calculated with the GATK “DepthOfCoverage” tool and areas 
that resulted with zero depth coverage, which implies bad mapping or a deletion, were 
subsequently identified with the Bash “grep” command in the obtained txt file. 
Analysis of the effect of non-synonymous SNPs with PROVEAN 
Amino acid changes as a result of non-synonymous SNPs were then categorised into 
neutral or deleterious changes, depending on the predicted impact on the biological 
function of a protein[30]. The Protein Variation Effect Analyzer (PROVEAN) tool for all 
species was used, which requires the protein sequence and affected amino acid, its position 
and the obtained variant, as an input. The standard cut-off score of -2.5 was used, which 
considers values below or equal to this threshold as deleterious and values above as 
neutral[31]. 
Investigation and visualisation 
Finally, genome wide depth of coverage was determined with a specialized function in the 
Bedtools software package, for each mapping file. The depth of coverage files was 
searched for regions that had zero depth of coverage, i.e. no reads map to these regions. 
This step produces a file for each isolate with a list of positions that indicate possible 
deletions. However, visual inspection of every region was required to determine if the 
region indicated was a true deletion. This visual inspection was done using Artemis[32]. 
 




3.9  Homologous recombineering  
For this study, the point mutagenesis via recombination technique adapted from van Kessel 
et al (2008)[33] was used. An in vitro point mutation was generated via a plasmid containing 
a recombineering gene, which required the selection of mutants from the selective media. 
The plasmid pJV75amber was used as a vector because it contained the gene, Che9c61 
which is responsible for recombination. An oligonucleotide containing the mutation was 
recombined into a transformed culture. This oligonucleotide was recombined into the 
bacterial genome owing to the activity of the Che9c61 gene. The methods were as follows: 
 
3.9.1  Oligonucleotide design for Homologous 
recombineering 
Oligonucleotides containing the SNP of interest were designed on the lagging strand of the 
relevant gene sequence of M. smegmatis reference gene[11], [33]. Subsequently, a nucleotide 
BLAST[34] was run to determine sequence homology between the relevant gene in M. 
smegmatis and M. tuberculosis H37Rv[11]. The gene regions had 100% query cover and 
identity between M. smegmatis and M. tuberculosis. Thus, it was determined that 
homologous recombineering could be done in M. smegmatis and parallels could be drawn 
between the mechanism in the two organisms due to the sequence homology. The 
oligonucleotides were ordered from IDT[35] and it was specified that they should be PAGE 
































Electrocompetent Eschericia coli cells 
A culture of Eschericia coli (E.coli) XL1 was streaked out on a Luria Agar plate to serve 
as a multiplication vector for the plasmid due to its fast doubling time. Single colonies 
were picked and sub-cultured in 100 µl Luria Broth (LB) overnight at 37˚C. A volume of 
20 µl culture was inoculated and grown in 100 ml LB to mid-log phase (OD600 = 0.8) at 
37˚C. Next, the culture was transferred into 50 ml sterile tubes and centrifuged at 5000 rpm 
at 4˚C for 20 min. The supernatant was discarded and the pellet was resuspended in 1 ml 
10% Glycerol. The wash step was repeated twice. Then the pellet was resuspended in 1 ml 










E.coli transformation with pJV75amber 
The pJV75amber plasmid (Figure 7) contains Kanamycin and Hygromycin resistance 
genes, thereby allowing for antibiotic selection. 
Figure 7. Plasmid pJV75amber[33] with origin of replication oriE confers expression of 
Che9c gp61 from the inducible acetamidase promoter. pJV75amber contains a 
hygromycin-resistant cassette (with two adjacent nonsense mutations which inactivate its 
function). 
The plasmid was eluted on 20 µl H20 and centrifuged at 13000 rpm for 5 min. Next, 1 µl 
pJV75amber was added to 100 µl E. coli competent cells and the cells were electroporated 
(Resistance: 200 ohms, Voltage: 2.5 kV, Capacitance: 125 µFD) in a Gene PulserTM[38]. 
Next, 500 µl SOC media was added and incubated at 37˚C for one hour. The transformed 
culture (25 µl, 50 µ, 100 µl) was then plated out onto Luria Agar containing Kanamycin 
(25 µg/ml) and incubated at 37˚C overnight. Single colonies were selected and cultured in 
10-15 ml LB broth containing Kanamycin (25 µg/ml) in a 50ml flask tube at 37˚C 
overnight. Glycerol stock (10%) cultures were aliquoted and stored at -80˚C. 
Transformation was confirmed by DraI and EcoRV restriction enzyme digestion and gel 
electrophoresis (100 Volts for 1.5 hours) on 0.8% 1x SB buffer agarose gel after staining 
with Ethidium Bromide. Subsequently, the pJV75amber plasmid was isolated by the 
Wizard® Plus SV Minipreps DNA Purification system[39]. 
 
 




Electrocompetent M. smegmatis cells 
M. smegmatis cells were cultured in Middlebrook 7H9 broth[3] supplemented with 0.05% 
Tween80 and 10% ADC at 37˚C until mid-log phase (OD600 = 0.5). The cells were 
harvested by centrifugation at 4000 rpm at 0˚C for 15 min. The supernatant was discarded 
and the pellet was resuspended in 50 ml Wash Solution (10% Glycerol containing 0.05% 
Tween80). The wash step was performed twice. The final pellet was resuspended in 1 ml 
Wash Solution and an aliquot of 200 µl culture was snap frozen in liquid nitrogen and 
stored at -80˚C. 
M. smegmatis transformation with pJV75amber 
The electrocompetent culture was centrifuged at 1500 rpm for 5 min at room temperature. 
The supernatant was discarded and the pellet resuspended in 100 µl Wash Solution. The 
wash step was repeated twice. A volume of 2 µl pJV75amber was added and the cells were 
electroporated (Resistance: 1000 ohms, Voltage: 2.5 kV, Capacitance: 125 µFD) in a Gene 
PulserTM[38]. Next, 900 µl of supplemented Middlebrook 7H9 broth was added and 
incubated for 3 hours at 37˚C. Then, the transformation culture (150 µl and 350 µl) was 
plated out on Middlebrook 7H10 plates[3] supplemented with 0.05% Tween80, 10% ADC 
and Kanamycin (25 µg/ml). Single colonies were picked and cultured in 10 ml of 
Middlebrook 7H9 broth[3] supplemented with 0.05% Tween80, 10% ADC and Kanamycin 
(25 µg/ml) at 37˚C for 2 days. The M. smegmatis culture was examined for contamination 
through Ziehl Neelsen staining. 
Electrocompetent M. smegmatis containing pJV75amber 
A volume of 100 µl M. smegmatis containing pJV75amber was cultured in 100 ml of 
Middlebrook 7H9 broth supplemented with 0.05% Tween80, 10% ADC, 20% succinate 
and kanamycin (25 µg/ml) at 37˚C until mid-log phase (OD600 = 0.4). Acetamide (1 ml) 
was added to the culture and incubated at 37˚C for 3 hours. The culture was put on ice for 
2 hours and centrifuged at 400 rpm at 0˚C for 15 min. The supernatant was discarded and 
the pellet was resuspended in 25 ml 10% Glycerol (sterile). The wash step was performed 
thrice, effectively halving the volume of the 10% Glycerol per step. The final pellet was 
resuspended in 1 ml 10% sterile Glycerol and an aliquot of 100 µl culture was stored at -
80˚C. 




M. smegmatis cells containing pJV75amber with oligonucleotide transformation 
The electrocompetent M. smegmatis culture was centrifuged at 1500 rpm for 5 min and the 
supernatant was discarded. The pellet was resuspended in 100 µl of 10% Glycerol with 
0.05% Tween 80. A volume of 1 µl (500 ng) of oligonucleotide for ndh 18, katG 347 and 
420 (see Table 8) was added in addition to Jcv198 oligonucleotide (5’-
CCCTGTTACTTCTCGACCGTATTGATTCGG[ATG]ATTCCTACGCGAGCCTGCGG
AACGACCAGG-3’) (mutant codon in square brackets) and the cells were electroporated 
(Resistance: 1000 ohms, Voltage: 2.5 kV, Capacitance: 125 µFD) in a Gene PulserTM[38]. 
Next, 900 µl of supplemented Middlebrook 7H9 broth was added an incubated at 37˚C for 
3 hours. Lastly, 110 µl transformation culture was plated onto Middlebrook 7H10 plates 
supplemented with 0.05% Tween80, 10% ADC and Hygromycin (100 µg/ml) at 37˚C for a 
duration of 4 days. 
Selection of mutants 
Single colonies were picked from the Middlebrook 7H10 plates supplemented with 0.05% 
Tween80, 10% ADC and Hygromycin (100 µg/ml) and cultured in 500 µl of Middlebrook 
7H9 broth[3] supplemented with 0.05% Tween80, 10% ADC and Hygromycin (100 µg/ml) 
at 37˚C for 2 days before PCR amplification and DNA sequencing. A volume of 100 µl 
50% Glycerol was added to 250 µl of mutant cultures and stored at -80˚C. 
PCR amplification and DNA sequencing ndh codon 18, katG codon 347 and 420 
Primers were designed to amplify individually codon 347 and 420 of katG as well as codon 
18 of ndh. This was done by making use of the genome sequence of the M. tuberculosis 
orthologue for the katG (MSMEG_6384[36]) gene in M. smegmatis, as well as the 
orthologue for the nat gene (MSMEG_0306[37]) and Primer software 3 version 0.2 [12]. The 









Table 9. Primers used for PCR amplification of homologous products 
Gene 






















The PCR mix [14] used per sample  for amplification on the Applied Biosystems thermal 
cycler 2720 is summarised in Table 10 and the PCR cycles in Table 11. 
 
Table 10. PCR mix for amplification of DNA for Standard Hotstart PCR 
Total mix 125 µl 
H2O 9.375 µl 
Q solution  5 µl 
10x buffer  2.5 µl 
MgCl2  2 µl 
dNTPs  4 µl 
Primer mix (2 primers)  50 µl 
Syto9 50 µl 
Qiagen Hotstart Taq[14]  0.125 µl 
DNA (from unpurified transformed M. smegmatis) 2 µl 
 




Table 11. PCR cycles for Hotstart 
 
 
After PCR, mutant screening was conducted via High Resolution Melt (HRM) on the 
Rotor Gene 6000[15]. All PCR products that showed amplification were then Sanger 
sequenced on the ABI PRISM DNA sequencer model 377[17] at the Central Analytical 
Facility (CAF) of Stellenbosch University. This was done with in order to confirm the 
presence of the introduced mutations. 
MIC determination of transformants 
M. smegmatis colonies that were transformed and mutant confirmed, were plated onto 
Middlebrook 7H10 agar supplemented with 0.05% Tween80, 10% ADC at varying 
concentrations of INH (0, 2, 8, 16, 32 µg/ml)[41] and incubated for 3 days at 37˚C. A total 
of sixteen colonies were picked from the selective media and subsequently cultured in 
Middlebrook 7H9 broth supplemented with 0.05% Tween80, 10% ADC and INH (8 
µg/ml) and incubated at 37˚C for 2 days. A total of 1 µl for each culture was spotted onto a 
Middlebrook 7H10 plate supplemented with 0.05% Tween80, 10% ADC and INH (16 
µg/ml) using a grid and incubated at 37˚C for 3 days. The preceding two steps were 
repeated by increasing the concentration of INH in 8 µg/ml increments until a 





Temperature  Time  Step 
95˚C 15 min Activation 
95˚C 45 sec Denature 
62˚C 45 sec Annealing 
72˚C 45 sec Extension 
72˚C 10 min Final Extension 
x45 
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3.1  Introduction 
The study collection period stretches from June 2014 to May 2016 and involved the 
identification of 397 M. tuberculosis isolates that were found to be susceptible to INH 
based on the genotypic test: GenoType MTBDRplus, but resistant with the phenotypic 
DST test using MGIT960TM. Samples originated from across the Eastern Cape and samples 
with discrepant results between the LPA and DST were identified at the NHLS Port 
Elizabeth Laboratory. 
3.2  MIC determination 
The MIC determination of the 397 clinical isolates used in this study was necessary to 
determine the level of resistance to INH for each isolate. Low-level resistance to INH is 
defined as growth between 0.1 and 1 µg/ml INH. High-level resistant status is designated 
to a sample if there is growth at concentrations higher than 1 µg/ml INH. Isolates are INH 
susceptible if no growth is observed below concentrations of 0.1µg/ml INH. 
As per these specifications, it was found that 42 (10.6%) of the clinical isolates were 
susceptible to INH, thus these isolates could be treated with INH effectively. Additionally, 
116 (29.2%) were found to be low-level resistant to INH per the MIC data. The relevance 
of this high proportion of INH low-level resistant isolates will be interpreted more in depth 
in the discussion section. It is of interest as patients with low-level resistant strains of M. 
tuberculosis could be treated with higher dosages of INH, and their drug treatment regimen 
does not have to be adjusted severely. 
A high proportion of the isolates (61%, n=242) from this study showed resistance to INH 
at varying degrees higher than 1 µg/ml. For 155 isolates, growth occurred at concentrations 
≥10 µg/ml INH. This effectively rules out INH as a treatment option as effective MIC 
cannot be clinically attained and alternative treatment regimens must be considered to treat 
these patients. For 10 isolates (2.5%) it was not possible to obtain MIC, as these were 
contaminated or lost viability. Table 12 below is a summary of the results of the resistance 








Table 12. Resistance status of clinical isolates by MGIT960TM MIC determination 
Resistance status Concentration Number of isolates 
Susceptible ≤0.1 28 
Low-level resistant >0.1 ≤1 116 
Resistant ≥10 155 
>5 ≤10 11 
>1 ≤5 76 
Contaminated (not M. 
tuberculosis) 
- 5 












3.3  Strain typing via spoligotyping 
 
The isolates included in this study were classified according to strain type by 
spoligotyping. Three spoligotype patterns were obtained for each isolate: the original 
culture and 2 samples from the MIC testing (the growth control and the tube with the 
highest concentration of INH where growth was observed). This was done to identify 
possible mixed infections which could have been the reason for the discrepancy of 
the INH testing methods.  
Table 13 below summarizes the proportions of the genotypes observed by 
spoligotyping of the original cultures. Out of the 397 isolates, 216 (54.4%) were 
found to be part of the Beijing family. The results observed were largely in 
accordance with the expectation based on the prevalence of the Beijing strain family 
in South Africa[1],[2]. Other major strain families identified include: LAM (9.3%), S 
(8.3%), EAI (6.8%), T (6.3%), X (4.8%), CAS (3.3%) and H (1.0%). We found 5 
different types for 7 different isolates that is not recoded in the International 
Spoligotype database (SITVIT[3]) and 1 of these patterns is of unknown 
family/lineage. The remaining 5.8% of isolates consisted of mixed infections 
(0.25%); unknown lineage (2.01%), one case of BCG (0.25%), 2 isolates with the 
MANU genotype (0.5%), non-tuberculosis mycobacteria (1.26%) and no spoligotype 
pattern could be obtained for 1.5% of isolates due to lost viability, contamination or 
not part of the Mycobacterium tuberculosis complex. This data is visually 
represented in Figure 8. 
We identified one original culture with a mixed infection of LAM and Beijing. A 
further four isolates with mixed infections were observed based on the spoligotype 
patterns. This is of interest as the presence of more than one strain type in a single 
isolate could potentially justify the discrepancies between the culture based method 
and molecular technique in diagnosing INH resistance. The statement “not in 
SITVIT” in the Table 13 indicates that the spoligotype pattern isn’t present on the 
SITVIT database. “Unknown” in the lineage or SIT family column means that the 
spoligotype pattern of this isolate does not resemble any known lineage or family 
markers.  




Table 13. Genotypes observed in sample set via spoligotyping  
Lineage N SIT family n SIT Spoligotype pattern n 
Beijing 216 BEIJING 212 1  212 
    BEIJING-LIKE 4 796  4 
LAM 37 LAM3 34 33  20 
        4  6 
        719  4 
        1293  1 
        1841  1 










    LAM9 1 42  1 
    LAM11_ZWE 2 815  1 
        2017  1 
S 33     34  28 
        71  3 








EAI 27 EAI1_SOM 21 48  20 
        806  1 
    EAI5 6 947  3 
        236  3 
T 25 T1 23 53  18 
        154  2 
        1112  1 
        2296  1 
        803  1 
    T3 2 37  2 
X 19 X1 4 119  2 
        2226  1 
        336  1 
    X2 4 137  3 
        478  1 
    X3 11 92  9 
        2286  1 
        2020  1 
CAS 13 CAS1_KILI 9 21  9 
    CAS1_DELHI 2 1092  1 




        26  1 





H 4 H1   62  1 
        610  1 





    H3   631  1 
Mix 1 BEIJING/LAM3   Mix  1 





Bovis 1 BOVIS1_BCG   482  1 
MANU 2 MANU1 1 337  1 
      1 100  1 
NTM 5 Possible NTM     

5 
no result 6       
 
6 
            397 
*If “no result” in the lineage column indicates that no results could be obtained for 
these isolates due to loss of viability due to contamination or this isolate could 












Figure 8. Proportion of genotypes observed via spoligotyping 
3.4  Sequencing of inhA promoter and katG 
We performed Sanger sequencing of katG gene and inhA promoter to identify mutations 
potentially associated with INH resistance. As in the case of the spoligotyping, we 
performed the PCR and sequencing on 3 samples per isolate: the original culture and 2 
samples from the MIC testing (the growth control and the tube with the highest 
concentration of INH where growth was observed).  
This was done to enable identification of possible mixed infections and to identify 
heteroresistance, when the M. tuberculosis strain is in the process of acquiring INH 
resistance, but would be missed by the LPA. 
It was found that the 42 samples that were susceptible to INH by MGIT960 MIC 
determination had wild type katG and inhA promoter. These samples were susceptible to 
INH on the LPA and were thus correctly diagnosed as they were susceptible on the DST as 
well. Sanger sequencing detected 8 isolates with classical mutations conferring resistance 

































presence of a mutant probe. Additionally, 7 isolates had mutations identified at codon 315 
of katG, which is different to the mutant probes of the LPA test, but should have been 
detected due to the absence of a wild type probe.  
By doing Sanger sequencing on the original culture and samples obtained from the MIC 
determination, we could identify 10 isolates that were in the process of gaining resistance 
to INH. These isolates were therefore classified as heteroresistant (resistant and susceptible 
in the same isolate). An example of the sequencing results of one these identified are given 












Figure 9. Image of Sanger sequencing results for as an example of heteroresistance.  
A: The Sanger sequencing results of the original sample, indicating codon 315 as wild type 
(AGC), although a slight peak of the mutant (C) is underlying. B: Sample of the growth 
control tube indicates the presence of both the wild type and the mutant. C: The sample 
from the tube that contained 10µg/ml INH, indicates only the mutant (ACC) present. The 












Additionally, Sanger sequencing of the areas surrounding the katG codon 315 and inhA 
promoter enabled identification 17 different mutations in 89 isolates. These mutations may 
have been the cause of INH resistance, but would have been missed by LPA method. See 
Table 14 and 15. 
For 200 (50.25%) of the isolates that were found to be resistant to INH, we could not 
identify a possible explanation for the discrepancy between genotypic and phenotypic 






















Table 14. Mutations identified via Sanger sequencing around katG codon 315 
Mutation identified 









2 bp ins at codon 346 of katG 1  Beijing 
katG 271 ACT-ATT 3  S 
katG 272 TTC-TCC 1  Beijing 
katG 273 GGT-GTT 2  Beijing 
katG  360 GGT-TGT 1  Beijing 
katG 279 GGC-GAC; inhA -77 
G-A 2 
 Unknown 
katG 285 GGC-GAC 
 
18 Beijing 
katG 291 GCT-GAT 2  Beijing 
katG 295 CAG-CCG 3  Beijing 
katG 300 TGG-CGG 2  T1 
katG 300 TGG-GGG 2  T3 
katG 325 CCG-CGG 1  Beijing 
katG 325 CCG-TCG 
 
1 Beijing 
katG 333 CTC-TTC 1  H3 
katG 337 TAC-TAG 1  Beijing 
katG 341 TGG-CGG 1  Beijing 
katG 347 CCT-CAT 1  T1 




Table 15. Mutations identified via Sanger sequencing around inhA promoter region 
Mutation identified 









inhA promoter -15 C-T  2 Beijing 
inhA promoter mix wt/-15 C-T 2  BEIJING/LAM3 
inhA promoter -17 G-T 2  Beijing 
inhA promoter-77 G-A 2  NOT IN SITVIT 
fabG1 12 CCA-CGA 1  X3 
Note, fabG1 is included in this table as it is an alternative promoter for inhA and increases 
its expression level[4]. Thus it is relevant for diagnostics. 
3.5  Sequencing katG 
Preliminary WGS results from a pilot investigation of 53 isolates with discrepant status 
indicated that a significant proportion had mutations elsewhere in the katG gene, thus 
outside the katG 315 region of M. tuberculosis. Mutations in this region serve as indicators 
of high-level resistance to INH per the LPA, thus mutations elsewhere in the katG gene 
would be missed by the molecular test but may be contributing to resistance. Thus, we 
performed Sanger sequencing on the entire katG gene for isolates with a mechanism of 
resistance that could not be elucidated via Sanger sequencing around the 315 region. Only 
SNPs confirmed to have a deleterious effect on the protein via PROVEAN[5] were 








Table 16: katG mutations outside region of LPA detection  
Mutation identified 









katG 346 TCC-TTC 1  Beijing 
katG 394 ACG-ATG 1  Beijing 
katG 412 TGG-TAG 1  F11/LAM3 
katG 406 GAC-AAC  1  EAI1_SOM  
katG 419 GAC-TAC 14  S 
katG 420 ATG-ACG 1  CAS1_KILI 
katG 421 GGT-CGT  1  Beijing 
katG 438 TGG-CGG 4  Beijing 
katG 439 CAG-CCG 
  
1 Beijing 
katG 457 AGC-ATC  1  Beijing 
katG 466 GGA-CGA  
 
1 Beijing 
katG 487 GAC-GAG 2  Beijing 
katG 501 CCA-TCA 1  S 
katG 538 GTC-TCC 1  Beijing 
katG 552 ATA-AAA 1  Beijing 
katG 553 GAG-AAG 1  X3 
katG 570 GGC-CGC 1  LAM3 




katG 594 TTC-CTC  1 Beijing 
katG 644 GGC-CGC  1  LAM3 
 
3.6  Whole Genome Sequencing Analysis 
We had the opportunity to perform WGS on a total of 130 of the first 300 isolates for 
which we were unable to find an explanation for INH discrepancies between DST 
techniques. This was done to search for other possible mechanisms of INH resistance in 
the genome of M. tuberculosis. The analysis of the results of the WGS revealed some 
interesting phenomena. In order to keep with the precedent set in the previous section, 
Table 17 below describes katG mutations that were missed by the LPA and Sanger 
sequencing. 
 
Table 17: katG mutations outside region of LPA detection observed via WGS 
 
Mutation identified 











large deletion (+/-199226) including 
entire katG 
1  X3 
large deletion (+/-19252 bp) including 
entire katG 
1  X3 
large deletion (+/-14671 bp) including 
entire katG 
1  
LAM3 and S 
/convergent 
katG deletion +/-  3268 bp (part of 
katG deleted) 
1  Beijing 
















katG deletion +/- 3232 bp (part of katG 
deleted) 
1  Beijing 
katG deletion +/- 1252 bp (part of katG 
deleted) 
2  
LAM3 and S 
/convergent 
katG deletion +/-  1045 bp (part of 
katG deleted) 
 
1  T1 
katG promoter -11 T-G 2  Beijing 
 
katG 1 GTG-GCG 
 
2  Beijing 
katG 1 GTG-GTA 1  T1 
katG 71 ATC-ACC + 91 TGG-CGG + 
121 GGC-CGC + 140 AGC-GGC 
 1 Beijing 
katG 91 TGG-CGG 5  Beijing (3) & S (2) 
katG 93 GCC-ACC  2 Beijing 
katG 94 GAC-GGC 4  Beijing 
katG 104 CGG-CAG 1  
LAM3 and S 
/convergent 
katG 104 CGG-TGG 1  LAM3 
katG 105 ATG- ATA 1  Beijing 
katG 109 GCT-GTT  1 LAM11_ZWE 
katG 113 TAC-TGC + katG promoter-
1 1 Beijing 

















katG 121 GGC-GTC 1  Beijing 
katG 121 GGC-CGC  1 Beijing 
katG 127 CAG-CCG 1  LAM3 
katG 138 AAC-AGC 1  Beijing 
katG 140 AGC-GGC  1 Beijing 
katG 142 GAC-GCC 5  Beijing 
katG 144 GCG-GTG 1  Beijing 
katG 172 GCG-ACG 2  Beijing 
katG 185 TTC- TTG 1  Beijing 
katG 189 GAC-CAC 1 1 Beijing 
katG 189 GAC-GGC  1 Beijing 
katG 203 CGG-CTG 1  Beijing 
katG 232 CCG-TCG 1 2 X2 
 1  S 
katG 380 ACT-ATT  1 Beijing 
katG 394 ACG-ATG  1 Beijing 
katG 419 GAC-TAC 1  S 
















katG 420 ATG-ACG  1 CAS1_KILI 
katG 421 GGT-AGT 1  T1 
katG 463 CGG-CTG 1  Beijing 
katG 479 GCG-CCG 1  Beijing 
katG 483 TTC-TCC 1  LAM3 
katG 496 CGC-GGC 1  Beijing 
katG 466 GGA-CGA + 594 TTC-CTC   1 Beijing 
katG 695 GAC-GGC 1  CAS1_KILI 
katG 711 TAT-GAT 1  Beijing 
 
Visual inspection via Artemis[6] revealed 1045 bp and 1252 bp deletions within the katG 
gene. Additionally, there were two isolates with deletions of +/- 3200 bp. The first was 
3232 bp which included the first 430 bp of katG and the second was 3268 bp which 
included the first 478 bp of katG. Interestingly, in a further 2 isolates we identified a 19 
kbp and a 14 kbp deletion that included the katG gene. These large deletions were missed 
by the initial screening as there is an underlying population with an intact wild type katG 
gene. Figure 10 displays these interesting large deletions obtained via Artemis analysis. 




 Figure 10. Visual inspection by Artemis to detect large deletions identified in the study 
A: result for sample 61 with +/-19 kbp deletion in majority of population (katG included). 
B: result for sample 66 with +/-14 kbp deletion in majority of population (katG included). 
For both figures the parts with low depth of coverage represents the deletions. These 
samples have mixed infections and the reads in the region with low depth of coverage 
represents the wild type strain that does not have the deletion. The pink shaded area 
represents the katG gene. 
 
Based on the results obtained via WGS and Sanger sequencing it is evident that a 
considerable proportion of isolates in this study had mutations in the katG gene that could 
be associated with INH resistance. Additionally, different mutations were associated with 
varying degrees of resistance. Based on this premise, Figure 11 shows all katG mutations 















Figure 11. All katG SNP mutations identified in this study and their associated level of 
resistance. 
Next, isolates were screened for mutations in genes (excluding katG) and promoters that 
have been linked to INH resistance per the literature[7],[8]. The genes include Rv0129c 
(fbpC)[9]; Rv0340[9]; Rv0341 (iniB)[9]; Rv0342 (iniA)[9]; Rv0343 (iniC)[9]; Rv1483 
(mabA)[9]; Rv1484 (inhA)[9], Rv1592c[9]; Rv1772[9]; Rv2242 (srmR)[9]; Rv2243 (fabD)[9]; 
Rv2247 (accD6)[9]; Rv3139 (fadE24)[9]; Rv3566c (nhoA)[9], Rv2245 (kasA), Rv2428 
(aphC) [10]; Rv1854c (ndh) [11], Rv1909c (furA) [12]; Rv2427a (oxyR) [13]; Rv2846c (efpA) 
[14];  Rv3795 (embB) [15]; Rv3199c (nudC); Rv3566c (nat); Rv0486 [16] and Rv3854C [17]. 
The promoter mutations included mutations at positions 1673356-1673439 (inhA 
promoter) [18]. The results for SNPs associated with low-level resistance to INH are 
summarised in Table 18. Conversely, Table 19 categorises the mutations that are 















Strain families of 
associated SNP 
Rv1592c 322 I/V 
Beijing, LAM3, 
H1, X2 & X3 
fabD 270 P/L LAM3 
fabG1 230 L/L LAM3 
inhA  194 I/T EAI1_SOM 
inhA 94 S/A Beijing, T1 & S 
ndh 18 V/A S 
 






Strain families of associated SNP 
Rv1592c 322 I/V 
Beijing, EAI1_SOM, EAI5, X1& 
T1 
 430 V/A T1 
accD6 229 D/G Beijing, EAI1_SOM, T1, X1 & S 
fabD 199 A/T T1 
fabG1 230 L/L S & X1 
fadE24 243 L/Q T1 
 430 M/L CAS1_KILI & CAS1_DELHI 
fbpC 158 G/S CAS1_KILI & CAS1_DELHI 









Strain families of associated SNP 
 158 & 160 G/S; S/A CAS1_DELHI 
inhA  194 I/T EAI5, EAI1_SOM & S 
iniA 481 H/Q EAI1_SOM & EAI5 
iniC 476 R/S EAI1_SOM & EAI5 
nat 207 G/R S 
ndh 18 V/A S 
 268 R/H EAI1_SOM & EAI5 
nhoA 207 G/R S 
nudC 126 S/A S 
 237 Q/P Beijing, EAI1_SOM & EAI5 
 239 P/R Beijing 
 72 P/S X1 
oxyR 13 L/F EAI1_SOM & EAI5 
 131 S/T EAI1_SOM & EAI5 
srmR 323 M/T CAS1_KILI & CAS1_DELHI 
 
No mechanism of resistance could be elucidated for six of the 130 WGS isolates per the 
current literature pertaining to SNPs associated with INH resistance. These included five 
isolates from strain family LAM3, of which three where low-level resistant and two was 
high-level resistant to INH. The last isolate was of Beijing lineage and high-level resistant 
to INH. 




When combining all the results obtained in this study, we were able to deduce the reason 
for INH testing discrepancies for 278 isolates (70%). However, for 119 isolates (30%) we 
are yet unable to elucidate the mechanism of INH resistance, and thus the reason for the 
discrepancies at the Routine laboratory. Table 20 below summarises the combined results 
obtained in this study. Note that the isolates with no elucidated mechanism of resistance to 
INH include the six that couldn’t be diagnosed via WGS, as well as isolates that were not 
whole genome sequenced and the mechanisms of resistance couldn’t be deduced via 
Sanger sequencing. Future studies will whole genome sequence the rest of the dataset. 
Table 20. Combined results of MIC, mutation analysis by Sanger sequencing and WGS 
Interpretation based on combined results 
# of isolates 
INH sensitive - wild type katG & inhA promoter 28 
INH resistant - mutations present (should have been detected by 
MTBDRplus) 
9 
INH resistant - mutations present - should have been detected by 
MTBDRplus (katG wt probe absent) 
3 
Low level resistance - inhA prom mutation identified (should 
have been detected with MTBDRplus) 
1 
Low level resistance - mutations present - should have been 
detected by MTBDRplus (katG wt probe absent) 
5 
INH resistant - mutation not part of MTBDRplus assay 
148 
Low level resistance - mutation not part of MTBDRplus assay 53 
INH resistant - mutations not detected by MTBDRplus due to low 
proportion (heteroresistance) 
7 
Low level resistance - inhA prom not detected by MTBDRplus 
due to low proportion (heteroresistance) 
4 
INH resistant - mutations not detected by MTBDRplus due to low 
proportion (mixed infections) 
6 
Low level resistance - mutations not detected by MTBDRplus due 
to low proportion (mixed infections) 
2 
BCG; intrinsic resistance 
1 
Contaminated / NTM 5 
INH resistant - no mutation identified 
72 
Low level resistance - no mutation identified 
47 
Lost viability 6 
Total 397 





3.7  Point Mutagenesis via Homologous recombineering 
 
Point mutagenesis served as functional validation of the effect of certain mutations on INH 
resistance. This was done by introducing single point mutations into a mycobacterial 
genome via oligonucleotide derived single-stranded DNA recombineering and 
mycobacteriophage-encoded proteins in a M. smegmatis strain carrying the replicating 
plasmid pJV75amber (Figure 7) that expresses Che9c gp61. This Che9c gp61-mediated 
recombination was efficient enough to introduce single base changes without direct 
selection, where the mutant strains were identified by PCR. Two genes implicated in INH 
resistance in this study were modelled in M. smegmatis per the method described by van 
Kessel et al.[19] Thus, by replacing a base pair within the gene at the specified position the 
adaption of M. tuberculosis is simulated and MIC’s were done to elucidate the effect on 
resistance. Figure 12 is the result of the Ziehl Neelsen staining done to confirm that the 
mutants generated were in fact mycobacteria. Observation of the culture under the 
microscope revealed acid fast bacilli consisting of straight and curved rods thus confirming 
that it is M. smegmatis and not a contaminant. 
 
Figure 12. Ziehl Neelsen stain confirming mycobacteria 




After the mutants were generated, Sanger sequencing was done in order to confirm that the 
SNP substitution had occurred. The ABI chromatograms represented by Figure 13 
illustrated that ndh colony 2 had a threonine substituted for a cytosine in codon 18 
(position 53). Note, the SNP is shown as being at position 253 bp and this is due to 200 bp 
upstream of the position of interest being sequenced as the mutation occurs close to the 
start of the gene – thus ensuring the desired region would be amplified accurately. Figure 
14 & 15 present the ABI chromatograms of the respective katG point mutants, where 
colony 9 of katG 347 had a cytosine substituted for an alanine and katG 420 colony 3 
contained the desired SNP of threonine substituted for a cysteine in the relevant codon. 







Figure 13. Colony of mutant M. smegmatis ndh with T-C substitution at position 53 (+200 



















Figure 15. Colony of mutant M. smegmatis katG 420 with T-C substitution at position 
1259 
Following confirmation that the SNP was present using Sanger sequencing, MIC 
determination was done on the ndh and katG mutant colonies and wild type M. smegmatis 
at varying concentrations (0, 0.1, 0.5, 1, 2, 4, 8, 16, 32 & 40 µg/ml) of INH per the 
literature for resistance[20]. This was done in order to validate the level of resistance to INH 
conferred by the mutation. Figure 16 shows growth of the wild-type at 0.1 µg/ml of INH. 
The radius of the colonies for MIC is depicted in centimetres (cm) and a double ended 
arrow (not to scale). Growth of the wild type in the presence of drug at a low concentration 
is within the parameters of expectation due to spontaneous mutation that occurs naturally 






































Figure 18. Minimum Inhibitory Concentration of M. smegmatis Colony 2 successfully 
transformed to have katG C347A mutation at varying concentrations of INH. 
0.1 µg/ml 0.5 µg/ml 
1 µg/ml 
2 µg/ml 
4 µg/ml 8 µg/ml 
16 µg/ml 32 µg/ml 
1 cm 0.8 cm 
0.6 cm 0.7 cm 
0.6 cm 0.3 cm 
0.1 cm 















Figure 19. Minimum Inhibitory Concentration of M. smegmatis Colony 9 successfully 
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Figure 20. Minimum Inhibitory Concentration of M. smegmatis Colony 3 successfully 
transformed to have katG T420A mutation at varying concentrations of INH. 
Low-level resistance to INH occurred in 25.6% of isolates per the MIC data suggesting 
that the Bangladesh regimen could be used effectively to treat these cases. Alternatively, 
60.3% of isolates were diagnosed as high-level resistant, thus necessitating alternative 
treatment regimens that exclude INH. Genotyping via spoligotyping revealed a prevalence 
of the Beijing genotype in this cohort, as well as mixed infections and novel spoligotype 
patterns that don’t resemble any known lineage or family markers. Sanger sequencing 
revealed canonical mutations that were missed by the LPA as well as mutations occurring 
elsewhere in the katG gene, indicating there are blind spots in the LPA that may have 
detrimental effects on patient response to treatment.  
 
0.1 µg/ml 0.5 µg/ml 
1 µg/ml 
2 µg/ml 





0.3 cm 0.1 cm 




Further analysis of genes associated with INH resistance via WGS revealed that 50.6% of 
isolates had resistance causative mutations in regions outside the region of hybridisation by 
the LPA, as well as large deletions in katG that would not have been detected via the 
molecular method. This serves as preliminary proof of the value of WGS as a diagnostic 
tool. Finally, homologous recombineering showed the functional effect of the ndh V18A, 
katG C347A and katG T420A SNPs on INH resistance. MIC data generated indicated that 
the ndh V18A mutation conferred high-level resistance to INH as growth occurred up to a 
concentration of 16 µg/ml of INH. Furthermore, per the MIC’s both the katG C347A and 
T420A SNPs conferred high-level resistance to INH, with mutant colonies showing growth 
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In Routine laboratories in South Africa, INH resistance in M. tuberculosis isolates are 
determined by means of the molecular method, Hain GenoType MTBDRplus. However, if 
this method predicted INH susceptibility and the isolate is RIF resistant, a second isolate 
will be cultured and conventional DST will be performed for INH. In this study, 397 
isolates were identified over a 2 year period by the regional NHLS laboratory in Port 
Elizabeth, to be scored by the LPA as susceptible to INH, but found to be resistant by 
conventional DST on the MGIT 960 system. Thus, we aimed to elucidate the reasons for 
the discrepancies between the 2 methods that are standardised and routinely used. The 
reason for discrepancies between genotypic and phenotypic INH resistance were 
subsequently tested via MIC, spoligotyping and Sanger sequencing and unknown 
mechanisms of resistance to INH were identified via whole genome sequencing. 
 
5.1 Rationalisation for discrepancy: level of drug resistance of non-
canonical SNPs 
 
Per our MIC determination, 10.6% of the clinical isolates were susceptible to INH. Thus 
these isolates were incorrectly diagnosed as INH resistant by the routine DST. Arguably, a 
potential reason for this could be the level of resistance to INH of the isolates. If the 
breakpoint is close to the critical concentration at which it is tested, false results may be 
generated. Alternatively, subculture of the original sample may have resulted in 
heteroresistance or mixed infection being selected out as this is the initial culturing step 
before INH is added, in favour of the susceptible form.  Lastly, lab error may have 
accounted for incorrect recording of results. Thus, complexities of the technique may result 
in inaccurate results, which could potentiate incorrect diagnosis of drug-resistant 
tuberculosis in patients. The current regimen of extended combined drug therapy for INH 
susceptible consists of rifampicin, isoniazid, ethambutol and pyrazinamide [1]. However, 
diagnosis of INH resistance may lead to the exclusion of INH in the regimen.  As INH  
serves as the backbone of treatment for drug sensitive tuberculosis infections due to its 
bactericidal effects against actively replicating bacilli [2], its exclusion may be detrimental 
to patient outcomes. 
 




Additionally, 116 (29.2%) were found to be low-level resistant to INH per the MIC data. 
Low-level resistance to INH has been associated with failure of tuberculosis therapy or 
relapse [3], as antibiotics will only act effectively if concentrations are above the MIC for 
M. tuberculosis and are adequately maintained (adequate area under the curve or “AUC”). 
For TB treatment, resistance to INH is commonly defined by an MIC of >1 µg/ml. In the 
South African context, the MICs of INH for approximately 50% of the INH resistant 
organisms studied were in the low-level resistance category, where low-level resistance to 
INH is characterised by an MIC between 0.1-1.0 µg/ml [4]. A study  done on animal models 
suggests that high doses of INH may be a viable treatment option for cases of low-level 
INH resistance in patients[5]. Van Deun et al. 2010 recommend high-dose INH as a 
supplement to 9 months of treatment with gatifloxacin, clofazimine, ethambutol, and 
pyrazinamide for treatment  of low-level INH resistant cases [6]. It was shown that a 
regimen lacking INH results in much lower effectiveness. This suggests that high-dose 
INH plays a vital role in treatment of MDR-TB [6]. We suggest that targeted treatment 
would yield even better outcomes. A similar conclusion was reached by an independent 
study [7], i.e. that high dose INH can be effective in the presence of the inhA gene 
mutations. 
 
Furthermore, we suggest that novel SNPs were observed in this study in low-level resistant 
isolates in genetic regions outside the hybridised regions of the LPA, viz.inhA promoter 
and katG. These polymorphisms, namely: Rv1592c I322V, fabD P270L, fabG1 L230L and 
ndh V18A would subsequently be missed by the LPA due to the selection bias in the 
molecular test. This may incorrectly exclude patients who may have benefited from the 
high dose regimen and unfavourably affect outcomes. 
 
The disregard for personalised dosage and diagnosis of low-level resistance may have 
severe consequences such as patients not responding to treatment optimally, particularly 
during the 4-month extension phase. Additionally, there is an increased risk for patient 
development of antibiotic resistance. Our own studies have shown that low-level INH 
resistance, as defined by mutations in the inhA promoter, are more common than mutations 
in katG in certain South African settings[8],[9]. This data suggests that such mutations 
conferring low-level resistance (and simultaneously including resistance to ETH) are a 




gateway to the development of further resistance, including high-level INH resistance, 
encoded by “classical” katG mutations that confer high-level resistance to INH [10].  
 
A high proportion of the isolates (61%, n=242) from this study showed resistance to INH 
at varying degrees higher than 1 µg/ml. Growth of 155 isolates occurred at concentrations 
≥10 µg/ml INH. This effectively rules out INH as a treatment option as effective MIC 
cannot be clinically attained and alternative treatment regimens must be considered to treat 
these patients.  
 
In summary, INH is likely a viable treatment option at high dosages for isolates that were 
resistant to INH at a low-level (<1ug/ml). A specific mutation, namely the inhA promotor, 
has been linked to lower levels of resistance in previous studies [11]. For 9.3% of the 
isolates, no mutations were identified in the classical loci conferring resistance to INH 
included in the LPA, and these isolates were all found to be susceptible to INH (MIC<0.1 
µg/ml). Additionally, for 4.5% of the isolates we identified a mutation at the loci 
represented on the LPA and these were found to be resistant with the MIC testing (>0.1 
µg/ml). 
 
5.2 Rationalisation for discrepancy: mixed infections/heteroresistance 
 
Another possible reason for the discrepancies between the two methods used by the routine 
laboratory could be due to INH resistant and susceptible bacteria being present in one 
isolate. This could be caused by two known ways. Firstly due to mixed strain infections, 
where the patient is infected by 2 different strains, a dominant susceptible strain and an 
underlying resistant strain[12]Secondly, when the bacteria are in the process of acquiring 
drug resistance, the population present in the isolates could have the wild-type population 
with the mutant population underlying, termed heteroresistance [13]. By the combination of 
Sanger sequencing and spoligotyping of the original cultures and the samples from the 
MIC determination, we were able to show the reason for the discrepancies were either 
mixed infection (n=8) or heteroresistance (n=11) in 4.8% of all the isolates. Sanger 
sequencing allowed for detection of underlying populations based on the ABI 
chromatograms. Simultaneously, Sanger sequencing was done to enable identification of 




possible mixed infections and to identify heteroresistance, when the M. tuberculosis strain 
is in the process of acquiring INH resistance, but would be missed by the LPA. . 
 
The LPA is not consequent in cases of mixed infection or heteroresistance, as the detection 
of mutations in the canonical regions is dependent on what population of M. tuberculosis 
(resistant or susceptible) is present in the greatest concentration. Thus, if the susceptible 
strain is dominant, the isolate will be misdiagnosed as susceptible to INH and the regimen 
prescribed will include INH to the detriment of the patient as it my perpetuate progression 
of resistance[14]. This hurdle may be overcome via culturing on selective media however, 
the DST is a secondary technique solely employed in cases of suspected drug resistance. 
Recommendation for culturing of all M. tuberculosis isolates (regardless of susceptibility 
or resistance) is logical but not necessarily viable due to the labour intensity and cost, 
which the molecular technique is intended to circumvent. Thus, cases of heteroresistance 
and mixed infection significantly complicate diagnoses as the primary technique employed 
for detection of INH resistance is not reliable. 
 
 
5.3 Rationalisation for discrepancy: BCG/ M. bovis 
 
We also identified one spoligotype pattern that indicates M. bovis/ BCG. A possible reason 
for it being missed by the LPA is that that the mutation that results in INH resistance is 
outside the region hybridised by the LPA. For instance, a study by Yang et al. in 2015 
found that the InbR gene, which regulates the expression of multiple genes as well as the 
iniBAC operon, serves as a repressor. This hypothesis was proven when overexpression of 
InbR protein decreased bacterial susceptibility to INH in M. bovis/ BCG[15]. Thus, an 
alternative mechanism of resistance (not caused by canonical mutations) would result in 











5.4 Mechanisms of INH resistance: katG 
By Sanger sequencing of the areas surrounding the mutations that are part of the LPA, we 
were able to identify additional mutations that are associated with resistance to INH. The 
specific genes and regions of M. tuberculosis that were amplified via PCR and Sanger 
sequenced are the katG gene and inhA promoter.  
5.4.1 Resistance affiliated with katG mutations 
The katG gene was selected for investigation for a number of reasons. Mutations in the 
katG gene are the most common mechanisms associated with INH resistance in M. 
tuberculosis [16], categorically associated with conferring medium to high-level resistance 
(minimum inhibitory concentration of > 1mg/ml) to INH [11],[17]. Thus, katG mutations are 
significant when inferring the mechanism of INH resistance. 
Mutations or deletions within the katG gene prevent the activation of INH upon its 
diffusion into M. tuberculosis, rendering INH ineffective against M. tuberculosis bacilli 
and resulting in high INH resistance levels [2],[11]. The catalase-peroxidase enzyme encoded 
for by the katG gene is often lost in highly resistant strains, however the catalase ability 
may be sustained in cases of low-level resistance caused by some katG mutations [2],[18],[19]. 
The katG S315T SNP has been strongly linked to high-level resistance to INH in the 
literature. According to Jeeves et al., 2015 this SNP is present in 50–90% of all isoniazid-
resistant clinical isolates[16]. This information is important for diagnostic and treatment 
purposes because it has been shown that initial mono-resistance to INH, specifically katG 
S315T mutations, often precede multi-drug resistance in M. tuberculosis [20].  
Thus, due to its significance, the S315T mutation is screened for in the LPA and should 
theoretically have been diagnosed as INH resistant if the SNP was present. However, 12 
isolates in this study had the canonical S315T mutation and were misdiagnosed as INH 
susceptible by the MTBDRplus LPA. We theorise that this is due to human error (perhaps 
subjective interpretation of results obtained) or possibly mixed infection with an 
underlying population of susceptible M. tuberculosis of the same genotype. 
Despite the significance of the canonical katG mutation, due to its prevalence and link to 
high-level resistance, mutations elsewhere in this gene may be causative of INH 




resistance[21] by increased susceptibility to oxidative stress, consequently resulting in 
adaption by upregulating the synthesis of a number of compounds involved in (i) increased 
uptake and use of alkanes and fatty acids as a source of carbon and energy and (ii) the 
synthesis of a number of compounds directly involved in reducing oxidative stress (REF). 
As indicated in Table 14 and 16, various SNP’s were identified elsewhere in this gene. 
Of particular interest in Table 14 is the katG G285D mutation, as it was identified in 18 
isolates, all of the Beijing lineage, and all low-level resistant to INH. As this SNP was only 
present in low-level resistant isolates, it is a good candidate for the justification of the high 
dose INH regimen. Kandler et al., 2018 found a missense mutation at this position in the 
gene and suggested its association with INH resistance based on the current 
literature[20],[22],[23], as well as confirming the rare katG W300G (Table 14) mutation has 
been experimentally associated with INH resistance in M. tuberculosis via functional 
genetics[22],[24]. 
The presence of katG SNP’s in low-level resistant isolates may be indicative of flaws in 
the premise of katG mutations being conferring medium to high level resistance to INH. 
There were other substitutions uncovered via Sanger sequencing in the katG gene in low-
level resistant isolates, however at lower proportions than katG G285D . These include an 
isolate with a SNP in katG S325P (Table 14), as well as single Beijing isolates with katG 
Q439P, G406R and F594L respectively (Table 16). A proportion (n=14) of high-level 
resistant isolates had a SNP in katG D419Y and as they were all part of the S family, it 
may be specific to this lineage, indicating possible transmission of an MDR-TB strain with 
high level of INH resistance.  
Furthermore, the results in Table 14 show isolates with double mutations in genes that 
may have a role in the mechanism of resistance. Torres et al., 2015 reported novel katG 
mutations, however that occurred either in combination with katG S315T or with -15C-T 
inhA promoter mutation [19]. Thus, it is not uncommon for combination mutations to be 
associated with INH resistance in M. tuberculosis. However, two isolates of unknown 
lineage had katG G279D as well as inhA -77 G-A SNP’s. These occurred in high-level 
resistant isolates and have not previously been reported in the current literature. 
Consequently, this may be a novel mechanism of resistance where adaption of the 
bacterium was causative of resistance at minimal fitness cost. Due to limited information 




available, it is difficult to infer with certainty the mechanistic role played by these 
mutations, but it serves as evidence of the complexities associated with drug resistance 
diagnoses as it is uncertain which SNP is causative of resistance or whether they both 
contribute. Future studies will investigate the effect of these combination mutations 
functionally. 
In summary, mutations detected in isolates with low-level resistance included inhA 
promoter -15 C-T and katG G285D, S325P, Q439P, G406R and F594L. Patients infected 
with a strain of M. tuberculosis containing these mutations serve as ideal candidates for 
inclusion of high dose INH within a treatment regimen, consequently limiting cases where 
first-line therapy is not prescribed. 
5.4.2 Resistance affiliated with katG deletions 
This body of work has established the role of mutations or deletions of the mycobacterial 
katG gene in INH resistance. Pretorius et al., 1995 stated that katG deletions are rare and 
not significant to resistance to INH[25], however our data suggests otherwise. Deletions of 
varying sizes in the katG genetic region are highlighted in Table 17. The large deletions 
identified are arguably the most significant finding of this study, were the two isolates with 
19 kbp are both of the X3 strain family. Although we can conclude with reasonable 
certainty that these deletions occur on two separate occasions due to the variation in size, 
there is insufficient data to draw irrefutable parallels with the phenomenon of large 
deletions and lineage.  
Three of the deletions span large areas (14 and 19 kbp) and various different genes are lost 
(see Figure 9). These deletions bring into question which compensatory mechanisms are at 
play, and future studies will confirm the presence of these deletions and functionally 
confirm their role in resistance and possibly fitness and virulence. The furA and katG 
promoters are deleted in both samples and thus further investigation must be done to find 
out how transcription of the rest of the genes downstream of the deletions are affected. It 
has been demonstrated in the literature that a deletion preceding the initiation codon of 
katG (thus including furA) was causative of high-level resistance to INH[26]. Per that 
publication, furA is essential for full catalase activity and INH susceptibility in M. 
tuberculosis and the deletion was responsible for the reduction of catalase-peroxidase 




activity in the isolate, thereby resulting in resistance to INH[26]. Tsolaki et al., 2004 
reported a similar case, where the entire katG gene was deleted, thereby conferring INH 
resistance[27]. The other four isolates with partially deleted katG genes are also significant, 
as codon 315 of katG is still intact and thus have resulted in a susceptible result with LPA. 
The katG promoter -11 T-G mutation in Table 17 is novel, as it has not been described in 
the literature to the best of our knowledge. We hypothesise that this SNP negatively affects 
transcription of the katG gene, thereby preventing InhA from binding and interrupting the 
INH mechanism of action and resulting in high-level resistance to INH in M. 
tuberculosis[28]. This is significant as the bacteria can survive and be virulent despite the 
defective promoter and thus suggesting compensatory mechanisms have evolved.  
The mutations in the katG start codon as observed in two isolates are also interesting, 
because it affects the recognition site of the start of the gene. The katG V1A mutation has 
previously been reported in INH high-level resistant isolates. Kandler et al., 2018 
confirmed the role of this SNP in INH resistance via functional genetics (point 
mutagenesis by homologous recombineering ) and stated that resistance was expected 
given that the GTG-GCG mutation meant that codon one would no longer be recognized 
as a start codon[22]. 
WGS revealed multiple mutations in a single isolate. However, unlike in section 5.4.1, the 
combination SNP’s summarised in Table 17 occurred in a single gene, namely the katG 
gene. Some combination mutations, such as katG Y113C + katG promoter -9 A-C, 
occurred in low and high-level INH resistant isolates. Alternatively, the combination 
mutations katG I71T + W91R + G121R + S140G and katG G466R + F594L occur solely 
in low-level resistant isolates. A potential reason for this may be that multiple mutations in 
a single gene could have a cascade effect on fitness cost, resulting in lower resistance. This 
reasoning is also applicable in cases of non-canonical mutations in alternative genes with 
known INH drug resistance associations. 
Coll., 2015[29] and Walker et al., 2015[30] serve as the current reference standards for SNPs 
that have defined roles in INH resistance. Subsequently, mutations such as katG W91R, 
A93T and D94G identified via WGS are considered novel mechanisms of resistance, as 
they have not yet been described in the literature to our knowledge. The katG 104 SNP had 
two variations in this cohort, where R104Q occurred in LAM3/S convergent high-level 




resistant isolate and R104W occurred in a LAM3 high-level resistant strain. This 
establishes a tenuous link between this mutation in this codon and lineage.  
There were also two different versions of the katG 121 SNP in Table 17. The katG G121V 
mutation resulted in high-level resistance in an isolate of Beijing lineage, whereas katG 
G121R resulted in low-level resistance in an isolate belonging to the same lineage. Other 
novel SNP’s conferring high-level resistance to INH include katG N138S, D142A, A144V, 
A172T, F185L, D189H, R203L, D419Y, G421S, R463L, A479P, F483S, R496G, D695G 
and Y711D. Potential candidates for the high dose INH regimen include low-level resistant 
isolates namely: katG S140G, D189G, T380I, T394M and M420T. 
5.5 Mechanisms of INH resistance: inhA promoter 
As stated in previous sections, mutations or polymorphisms in the inhA promoter are the 
second most common explanation for INH resistance. The mutations detected included the 
fabG1 gene as serves as an alternative promoter for inhA, thereby increasing expression 
level and cementing its relevance for next generation molecular diagnostics[19],[22],[31]. More 
specifically, investigation of INH resistant isolates showed that a -15 mutation in the inhA 
promoter was on average present in 19.5% of isolates from 49 different countries [23]. Low-
level resistant Beijing isolates with this mutation can be observed in Table 15. Moreover, 
this mutation was seen in as many as 43% of INH resistant cases in specific geographical 
locations, thus its link to resistance is well established [23] and strains with these mutations 
spread more rapidly than strains with other mutations [8],[32]. Resistance caused by inhA 
promoter mutations is typically low-level (MIC of less than 1 µg/ml) [11].  
However, the data in Table 15 categorises the non-canonical inhA promoter mutations 
detected in this study via Sanger sequencing as being present in high-level resistant 
isolates. A possible reason for the higher level of resistance is mixed infections, where the 
low-level resistant population may be present at lower proportions and thus not detected. 
Additionally, MIC would select for the high-level resistant population, as the lower 








5.4.2 Mechanisms of INH resistance: SNPs in other genes associated with 
INH resistance 
 Other genes (excluding katG and inhA promoter) also have also been reported to be 
associated with resistance to the first-line antibiotic INH (REFs). Some SNPs such as 
Rv1592c I322V, fabG1 L230L, inhA I194T and ndh V18A identified by WGS, were 
present in low and high-level INH resistant isolates. Thus, the only candidates for the 
Bangladesh INH high-dose regimen in Table 18 are the strains harbouring fabD P270L 
and inhA S94A. 
The role of these alternative genes in INH resistance vary. For instance, SNP’s in the 
Rv1592c, fadE24, iniA, iniC and srmR genes have been implicated in INH resistance, but 
the functional mechanism remains speculative/unknown and the level of resistance is 
inconclusive[23],[33]. However, the mechanism of action is well defined in fabD as it a 
malonyl CoA:ACP transacylase[34] as well as in the fabG1-inhA regulatory region, which 
serves as an alternative promoter for inhA[19].  
Mutations in the inhA open reading frame of M. tuberculosis are not as common as in katG 
or inhA promoter, but still occur often enough to be of interest [18]. The S94A mutation in 
inhA decreases INH-NAD Adduct affinity for the NADH-binding site of InhA, 
subsequently resulting in increased INH as well as ethionamide resistance [35]. Other 
mutations in the inhA gene that have been associated with INH resistance encompass 
mutations at codons I21T/V, A190S, I194T and I258T/V [23],[35]. As a result of the different 
mutations in this region that have been associated with INH resistance, as well as the 
prevalence of mutations in this region being associated with low-level INH resistance, it 
can be assumed that the inhA gene coding region is significant to INH action and 
resistance. 
The accD6 D229G mutation in Table 19 has been shown to play a role in the building 
blocks for de novo fatty acid biosynthesis in the literature[19]. Similarly, the fbpC gene has 
a role in mycolyltransferase activity that is vital for the formation of cord factors, and if 
disrupted with mutations affects the INH mechanism of action as INH targets the type 2 
fatty acid synthase (FAS II) system in M. tuberculosis. Thus, by preventing the synthesis 
of mycolic acids, the fbpC SNP is directly affecting the target of INH.   




Finally, the ahpC-oxyR intergenic region is thought to be responsible for the regulation of 
katG expression[21]. Both the ahpC and oxyR genes are up regulated in M. tuberculosis 
under conditions of oxidative stress. The promoter region of ahpC acquires mutations 
when katG is absent or mutated and there is no catalase or peroxidase activity[2]. These 
polymorphisms result in the production of an alkylhydroperoxide reductase enzyme that 
performs the same function to compensate for the absence of catalase peroxidase[2] The 
oxyR gene is also upregulated either to combat peroxidation in the absence of katG or to 
activate katG expression[36],[37]. 
Although we were able to identify the possible mechanism of INH resistance in most of the 
isolates through WGS, there were still 9 isolates were no mutations detected by USAP, 
Artemis or the variant files in any of the known genes that could have resulted in INH 
resistance. Thus, the cause of resistance for these isolates remains unknown.  
It is concerning that highly resistant cases would have been missed entirely if the LPA was 
the sole method of resistance testing. These INH resistant cases were only discovered due 
to secondary DST resistance testing. These culturing methods are not a solution to the 
problem, as they are time consuming, which is problematic if the patient is on inadequate 
treatment and is potentially spreading the disease further in the community. 
Furthermore, it has been observed in literature [13], as well as in the results of this study, 
that the LPA is not 100% effective in detecting mutations in the regions it does hybridize 
to. It is also not an effective means of resolving/diagnosing resistance when 
heteroresistance or mixed infections occur. Mixed infections require additional testing 
beyond just the LPA to be detected, as only the population present in the highest 
proportion would be detected by the LPA. The patient would be incorrectly diagnosed as 
having a drug susceptible strain of INH and the incorrect drug treatment regimen would be 
prescribed. 
It is hypothesized that the usually uncommon mutations observed in this study are 
observed more frequently for one of two reasons (or a combination): The first reason is 
that they occur due to an outbreak in this region. However, this only applies to isolates in 
this study that have mutations that occur in multiple isolates from the same strain lineage. 
The second reason is that there are systems in place to test for and treat well-known 
mutations such as the katG 315 mutation that is readily detected by the LPA in most 




instances. Thus, the common mutations are treated, giving the rarer mutations the 
opportunity to prevail.  
Since a number of mutations in other regions of katG (not surrounding codon 315) were 
detected, sequencing the rest of the katG gene may be useful as a first line approach to 
identify uncommon mutations causing INH resistance.  
Additionally, a significant amount of isolates have been identified to be resistant to INH 
but not have the classical mutations tested for by molecular test such as the LPA. Thus, the 
current drug resistance testing algorithm used is logical. The data suggests that it is not 
sufficient to employ the LPA as the sole resistance testing mechanism in all cases that are 
not diagnosed as rifampicin mono-resistant. Instead, it serves as evidence that the 
secondary phenotypic DST may have to be employed in all cases, whether the isolates are 
found to be susceptible or resistant to INH, to ensure that no incorrect diagnoses are made. 
Although, it should be noted, that this is time consuming and expensive and should thus 
not be the sole solution to the current problem of discrepancies in detection of resistance 
causing mutations for routine laboratories. Our recommendation is that WGS could be 
implemented in order to minimize the chances of missing non-canonical INH resistance 
mutations outside targeted hotspots and identify acquisition of resistance (heteroresistance) 
earlier. Future studies should obtain WGS data for all isolates in this study in order to 
ensure that no novel SNPs go undiagnosed, and to ensure there is no bias. 
5.4.3 Confirmation of INH resistance mechanisms by Point Mutagenesis 
in M. smegmatis via homologous recombineering 
Single point mutations were generated in suspected drug targets of a wild-type M. 
smegmatis model using oligonucleotides. M. smegmatis is well established as a model for 
M. tuberculosis[38] due to its non-virulence and fast-growing status. This technique has 
been adapted from van Kessel et al., 2008 and results in high recombination frequency in 
M. tuberculosis and M. smegmatis[38] when an oligonucleotide binds to the lagging strand 
of single stranded DNA. The purpose of this was to investigate the role of individual SNPs 
identified by WGS in this study role in INH resistance. The three single point mutations 
sucessfully generated were ndh V18A, katG C347A and katG T420C. The presence of the 
polymorphism was confirmed via Sanger sequencing in each and the effect was measured 
via MIC. 




Cardoso et al., 2007, hypothesised that a mutation in ndh V18A could be associated with 
resistance as a mutation in this gene could result in an alteration of the NADH/NAD+ 
ratio[39]. This prevents the peroxidation reactions required for the activation of INH, as well 
as the displacement of the NADH-isonicotinic acyl complex from InhA enzyme binding 
site. This study found a V18A mutation in five INH high-level resistant isolates and one 
low-level, thus establishing a tenuous link to resistance. This mutation was also 
encountered in both resistant and susceptible strains by Hernando Hazbon et al., 2006. 
Thus, this SNP was selected, to confirm or refute its role in INH resistance. Additionally, a 
search using the program PROVEAN revealed that the influence of this SNP on the protein 
is deleterious and thus affects the functioning of the gene. 
MSMEG_0306[40] was selected as the reference sequence due to its high genetic homology 
(93% query cover per NCBI BLAST[41]) to the ndh (Rv1854c) gene of M. tuberculosis. 
This was done with the with the purpose of inferring the effect of resistance from the 
model. The four colonies containing the SNP were cultured in increasing concentrations of 
INH and the MIC for INH in the ndh mutants was > 8 µg/ml after three days of incubation. 
As INH resistance is categorised as “high-level” at minimum inhibitory concentration 
(MIC) of > 1 µg/ml INH, the results obtained indicate that the ndh V18A polymorphism 
confers high-level resistance to INH in M. smegmatis.  
Selecting an orthologue for the katG gene in M. smegmatis was more complex than for 
ndh, as there are three possible options. These are MSMEG_3729, MSMEG_3461 and 
MSMEG_6384. However, MSMEG_6384 was found to have  the greatest sequence 
homology to katG (Rv1908c) of M. tuberculosis with a query cover of 95%[41]. The 
justification for the investigation of uncharacterised katG mutations is that the LPA 
MTBDRplus screens for mutations in regions of katG and inhA promoter which are known 
to be associated with INH resistance[3]. The LPA tests specifically for mutations in katG 
315 (S315T1 and S315T2) as these mutations are most commonly associated with 
resistance to INH[2], as well as -15 (C15T), -16 (A16G) and -8 (T8C/T8A) mutations in the 
inhA promoter (Albert et al., 2010). Thus, any mutations that cause INH resistance, but 
occur outside these specific regions (such as the katG mutations in this study) will be 
missed by the LPA, thereby misdiagnosing the patient as INH susceptible. Therefore, it is 
vital to ensure that all mutations that are suspected to confer INH resistance are confirmed, 
with the purpose of improving current diagnostic methods. 




The point mutation in katG C347A was selected for genetic functional validation as it has 
not been associated with INH resistance in the literature[29],[30], thus it may be a novel 
mechanism of resistance. A single high-level resistant isolate containing this SNP was 
identified in the subset via Sanger sequencing (see Figure 10). Functional genetics 
confirmed this finding as the MIC for the single mutant colony was < 8 µg/ml of INH as 
seen in Figure 25, indicating that the base pair change confers high-level resistance in the 
model. The katG T420C mutation was encountered in one low-level and one high-level 
resistant isolate in our dataset as seen in Figure 10. A clear link to resistance has not been 
established per the literature[29],[30]. The results in Figure 26 indicate that mutant colony 3 
has an MIC of > 8 µg/ml of INH and confers high-level resistance. The MIC’s obtained for 
each point mutation is vital, as knowledge on SNPs and the level of resistance they cause is 
limited[42].  The variation in growth shows that different resistance mutations lead to 
specific MIC’s, where those conferring low-level resistance may still be treated by 
increased dosing.  
However, despite the results of this experiment showing promise, there are certain 
limitations to the homologous recombineering experiment. The pJV75amber plasmid used 
as a vector could potentially initiate other undesireable recombination events which may 
have an influence on INH resistance. Additionally, the use of M. smegmatis allows 
inference as to the potential effects of the point mutations in M. tuberculosis but are not 
entirely conclusive. 
Future studies will aim to overcome these hurdles by performing homologous 
recombineering in H37Rv and sequencing the entire genome using WGS. Then the 
genome of wild-type could be compared to the recombineered H37Rv in order to confirm 
there are no alternative mechanisms that are causative of resistance. Alternatively, further 
possible recombineering events caused by the Che9c 61 gene can be eliminated via curing 
of the pJV75amber plasmid by several passages on media that doesn’t contain the selective 
drugs (Kanamycin and Hygromycin). If the plasmid is successfully removed and the 
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6.2 Limitations of study 
 
The data presented in this thesis was investigated to derive the reason for discrepancies 
between the LPA and DST with the purpose of informing the current drug resistance 
testing algorithm for INH. However, there were a number of limitations that could have an 
impact on the results obtained. The first is the lack of clinical data for the isolates 
investigated, as there may be multiple isolates from a single patient. This may result in 
over or underestimation of the prevalence of specific SNPs in this cohort. Secondly, whole 
genome data was only obtained for a subset of 130 of the 397 isolates. As a result, some 
resistance causing mutations in alternative genes (excluding the katG gene and inhA 
promoter region) may have been missed. The homologous recombineering experiment also 
had various limitations. For instance, the use of M. smegmatis as a model allows inference 
as to the potential effects of the point mutations in M. tuberculosis but it is not conclusive 
that the impact will be the same in the virulent bacteria. Additionally, the vector used could 
potentially have initiated other undesireable recombination events which may have 
influenced INH resistance. 
 
6.2 Future Studies 
 
Future studies will minimise the impact of the abovementioned limitations. Applications 
for ethical approval to access to clinical data are currently underway. Whole genome 
sequencing will be done on the entire dataset to ensure the correct mechanism of resistance 
has been elucidated for each isolate. Furthermore,  homologous recombineering will be 
initiated in H37Rv and the entire genome will be investigated via means of WGS. This will 
allow comparison between the genome of wild-type and recombineered H37Rv in order to 
confirm there are no alternative mechanisms that are causative of resistance. Alternatively, 
further possible recombineering events caused by the Che9c 61 gene can be eliminated via 
curing of the pJV75amber plasmid by several passages on media lacking selective drugs. 
Succesful removal of the plasmid with persisting resistance to INH is indicative of the 
mutation inserted being the cause of resistance. 
 




























As hypothesised, some of the discrepancies between LPA and DST can be attributed to 
unknown mechanisms of resistance in this cohort. Novel mutations or deletions as well as 
mutations present elsewhere in the M. tuberculosis genome have been identified in a large 
proportion of cases as the cause for INH resistance. Thus, an alternative or updated drug 
resistance testing algorithm for INH resistance may be required.  
Per the results of this study, it is evident low-level INH resistance is an underrated 
component of the global TB epidemic worldwide, and may be a significant problem in 
terms of progression to antibiotic resistance and treatment outcome. Low-level resistance 
can lead to progression to multi-drug resistance. We need to investigate this carefully and 
test whether personalised diagnostics and targeted high dose treatment with INH will 
reduce the incidence of isoniazid mono-resistant and multi-drug resistant (MDR) 
tuberculosis.  
Additionally, a significant amount of isolates have been identified to be resistant to INH 
but not to have the canonical mutations tested for by molecular test such as the LPA and a 
small proportion were misdiagnosed due to lab error. Thus, the current drug resistance 
testing algorithm used is logical. The data suggests that it is not sufficient to employ the 
LPA as the sole INH resistance testing mechanism in all cases that are diagnosed as 
rifampicin resistant. Instead, it serves as evidence that the secondary phenotypic DST may 
have to be employed in all cases, whether the isolates are found to be susceptible or 
resistant to INH and at more than one drug concentration. Multiple concentrations of drug 
in DST would uncover the extent of resistance to ensure correct diagnoses are made to 
inform the antibiotic regimen. Although, it should be noted, that this is time consuming 
and expensive and should thus not be the sole solution to the current problem of 
discrepancies in detection of resistance causing mutations for routine laboratories.  
Our recommendation is that WGS should be implemented in order to minimize the chances 
of missing non-canonical INH resistance mutations outside targeted hotspots. Future 
studies should obtain WGS data for all isolates in this study in order to prevent novel SNPs 
from being undiagnosed, and to ensure there is no bias. The findings of this study may 
inform diagnostic algoritms and WGS analysis for improved testing for INH resistance. 
Additionally, a better understanding of the mechanisms of resistance will aid in devising 
new strategies to overcome drug-resistance. 






Reagents used for MGIT 
 
MGIT medium 
A MGIT 960 tube contains 7.0 ml of modified Middlebrook 7H9 broth base. The 
approximate formula per 1000 ml purified water is: 
 Modified Middlebrook 7H9 broth base  -------- 5.9 g 
 Casein peptone  ----------------------------------- 1.2 g 
 Add supplements as required. 
 
MGIT Growth supplement (OADC) 
MGIT growth supplement is used for the preparation of subcultures and inoculate and 
contains 15 ml of the following per liter of water. 
 
 Bovine albumin -------------------- 50.0 g 
 Dextrose----------------------------- 20.0 g 
 Catalase ----------------------------- 0.03 g 
 Oleic acid ---------------------------- 0.1 g 
 Polyoxyethyline state --------------- 1.1 g 
 
Solutions used for spoligotyping 
 
Working stocks  
 
500ml 2xSSPE/0.1%SDS:  
 100ml 10x SSPE  
 5ml 10% SDS  
 dH2O to 500ml  
 
1000ml 2xSSPE/0.5%SDS:  
 200ml 10x SSPE  
 50ml 10% SDS  
 dH2O to 1000ml  
 




1000ml 1% SDS:  
 100ml 10% SDS  
 dH20 to 1000ml  
 
500ml 20mM EDTA:  
 25ml 0.5M EDTA  
 dH2O to 500ml  
 
Stock solutions  
 
10x SSPE:  
 13.7g Sodium hydrogen Phosphate – 100mM  
 105.19g Sodium Chloride – 1.8M  
 3.36g EDTA – 10mM  
 dH2O to 1000ml  
 pH = 7.40  
 
10% SDS:  
 50g SDS  
 dH2O to 500ml  
 
0.5M EDTA:  
 93g EDTA  
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